Fulgent Genetics (FLGT) 10-Q 7 Nov 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 01, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Trading Symbol	FLGT
Entity Registrant Name	FULGENT GENETICS, INC.
Entity Central Index Key	0001674930
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		29,438,052
Entity File Number	001-37894
Entity Tax Identification Number	81-2621304
Entity Address, Address Line One	4978 Santa Anita Avenue
Entity Address, City or Town	Temple City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91780
City Area Code	626
Local Phone Number	350-0537
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 168,770	$ 164,894
Marketable securities	402,290	285,605
Trade accounts receivable, net of allowance for credit losses of $35,410 and $11,217	104,159	138,912
Other current assets	21,395	22,549
Total current assets	696,614	611,960
Marketable securities, long-term	346,946	485,047
Redeemable preferred stock investment	11,233	21,965
Fixed assets, net	81,807	62,287
Intangible assets, net	87,853	35,914
Goodwill	120,313	50,897
Other long-term assets	61,016	10,650
Total assets	1,405,782	1,278,720
Current liabilities
Accounts payable	14,481	20,494
Accrued liabilities	25,101	17,689
Income tax payable	426	787
Contract liabilities	2,603	14,570
Customer deposit	25,810	19,806
Investment margin loan	14,999	15,137
Contingent consideration		10,000
Notes payable, current portion	5,481	6,147
Other current liabilities	13,621	680
Total current liabilities	102,522	105,310
Unrecognized tax benefits	1,826	725
Other long-term liabilities	20,037	6,805
Total liabilities	124,385	112,840
Commitments and contingencies (Note 8)
Stockholders’ equity
Common stock, $0.0001 par value per share, 50,000 shares authorized, 30,667 shares issued and 29,681 shares outstanding and 30,160 shares issued and outstanding	3	3
Preferred stock, $0.0001 par value per share, 1,000 shares authorized, no shares issued or outstanding
Additional paid-in capital	477,814	501,908
Accumulated other comprehensive loss	(25,602)	(759)
Retained earnings	824,832	657,597
Total Fulgent stockholders' equity	1,277,047	1,158,749
Noncontrolling interest	4,350	7,131
Total stockholders’ equity	1,281,397	1,165,880
Total liabilities and stockholders’ equity	$ 1,405,782	$ 1,278,720

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Allowance for credit losses	$ 35,410	$ 11,217
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	30,677,000	30,160,000
Common stock, shares outstanding	29,681,000	30,160,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (unaudited) - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenue	$ 105,655,000	$ 227,868,000	$ 551,264,000	$ 740,913,000
Cost of revenue	59,560,000	43,466,000	197,350,000	153,399,000
Gross profit	46,095,000	184,402,000	353,914,000	587,514,000
Operating expenses:
Research and development	7,507,000	6,021,000	20,401,000	16,755,000
Selling and marketing	9,859,000	6,012,000	28,665,000	16,239,000
General and administrative	26,266,000	12,299,000	82,281,000	28,630,000
Amortization of intangible assets	2,006,000	797,000	4,487,000	797,000
Restructuring Costs	105,000		3,001,000
Total operating expenses	45,743,000	25,129,000	138,835,000	62,421,000
Operating income	352,000	159,273,000	215,079,000	525,093,000
Interest and other income, net	1,405,000	496,000	2,408,000	1,382,000
Income before income taxes and gain on equity method investment	1,757,000	159,769,000	217,487,000	526,475,000
Provision for income taxes	414,000	37,545,000	51,488,000	127,647,000
Income before gain on equity method investment	1,343,000	122,224,000	165,999,000	398,828,000
Gain on equity method investment				3,734,000
Net income from consolidated operations	1,343,000	122,224,000	165,999,000	402,562,000
Net loss attributable to noncontrolling interests	376,000	298,000	1,236,000	463,000
Net income attributable to Fulgent	$ 1,719,000	$ 122,522,000	$ 167,235,000	$ 403,025,000
Net income per common share attributable to Fulgent:
Basic	$ 0.06	$ 4.13	$ 5.53	$ 13.79
Diluted	$ 0.06	$ 3.93	$ 5.38	$ 13.04
Weighted-average common shares:
Basic	30,174	29,673	30,256	29,221
Diluted	30,867	31,170	31,107	30,906

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Net income from consolidated operations	$ 1,343	$ 122,224	$ 165,999	$ 402,562
Other comprehensive income (loss):
Foreign currency translation loss	(1,925)	(114)	(3,680)	(78)
Net (loss) gain on available-for-sale debt securities, net of tax	(2,502)	142	(22,708)	(587)
Comprehensive (loss) income from consolidated operations	(3,084)	122,252	139,611	401,897
Net loss attributable to noncontrolling interest	376	298	1,236	463
Foreign currency translation loss attributable to noncontrolling interest	1,242	25	1,545	15
Comprehensive loss attributable to noncontrolling interest	1,618	323	2,781	478
Comprehensive (loss) attributable to Fulgent	$ (1,466)	$ 122,575	$ 142,392	$ 402,375

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($) $ in Thousands	Total	November 2020 Equity Distribution Agreement	Cumulative Effect, Period of Adoption, Adjustment	Stockholders' Equity	Stockholders' Equity November 2020 Equity Distribution Agreement	Additional Paid-In Capital	Additional Paid-In Capital November 2020 Equity Distribution Agreement	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Retained Earnings Cumulative Effect, Period of Adoption, Adjustment	Fulgent Stockholders' Equity	Fulgent Stockholders' Equity November 2020 Equity Distribution Agreement	Fulgent Stockholders' Equity Cumulative Effect, Period of Adoption, Adjustment	Noncontrolling Interest
Beginning Balance at Dec. 31, 2020	$ 569,387		$ (887)	$ 3		$ 418,065		$ 438	$ 150,881	$ (887)	$ 569,387		$ (887)
Beginning Balance, Shares at Dec. 31, 2020				28,178,000
Equity-based compensation	2,962					2,962					2,962
Exercise of common stock options	44					44					44
Exercise of common stock options, Shares				45,000
Restricted stock awards, Shares				187,000
Common stock withholding for employee tax obligations	(513)					(513)					(513)
Common stock withholding for employee tax obligations, Shares				(4,000)
Issuance of common stock		$ 30,297					$ 30,297					$ 30,297
Issuance of common stock, Shares					583,000
Other comprehensive income (loss)	(654)							(654)			(654)
Cumulative tax effect of accounting change	239								239		239
Net income (loss)	200,691								200,691		200,691
Ending Balance at Mar. 31, 2021	801,566			$ 3		450,855		(216)	350,924		801,566
Ending Balance, Shares at Mar. 31, 2021				28,989,000
Beginning Balance at Dec. 31, 2020	569,387		$ (887)	$ 3		418,065		438	150,881	$ (887)	569,387		$ (887)
Beginning Balance, Shares at Dec. 31, 2020				28,178,000
Net income (loss)	402,562
Ending Balance at Sep. 30, 2021	1,044,453			$ 3		483,731		(212)	553,258		1,036,780			$ 7,673
Ending Balance, Shares at Sep. 30, 2021				29,829,000
Beginning Balance at Mar. 31, 2021	801,566			$ 3		450,855		(216)	350,924		801,566
Beginning Balance, Shares at Mar. 31, 2021				28,989,000
Equity-based compensation	3,526					3,526					3,526
Exercise of common stock options	24					24					24
Exercise of common stock options, Shares				4,000
Restricted stock awards, Shares				143,000
Common stock withholding for employee tax obligations	(39)					(39)					(39)
Common stock withholding for employee tax obligations, Shares				(1,000)
Issuance of common stock	27,889					27,889					27,889
Issuance of common stock, Shares				378,000
Noncontrolling interest assumed related to acquisitions	8,151													8,151
Other comprehensive income (loss)	(39)							(49)			(49)			10
Net income (loss)	79,647								79,812		79,812			(165)
Ending Balance at Jun. 30, 2021	920,725			$ 3		482,255		(265)	430,736		912,729			7,996
Ending Balance, Shares at Jun. 30, 2021				29,513,000
Equity-based compensation	4,374					4,374					4,374
Exercise of common stock options	17					17					17
Exercise of common stock options, Shares				25,000
Restricted stock awards, Shares				320,000
Common stock withholding for employee tax obligations	(2,915)					(2,915)					(2,915)
Common stock withholding for employee tax obligations, Shares				(29,000)
Other comprehensive income (loss)	28							53			53			(25)
Net income (loss)	122,224								122,522		122,522			(298)
Ending Balance at Sep. 30, 2021	1,044,453			$ 3		483,731		(212)	553,258		1,036,780			7,673
Ending Balance, Shares at Sep. 30, 2021				29,829,000
Beginning Balance at Dec. 31, 2021	$ 1,165,880			$ 3		501,908		(759)	657,597		1,158,749			7,131
Beginning Balance, Shares at Dec. 31, 2021	30,160,000			30,160,000
Equity-based compensation	$ 5,616					5,616					5,616
Exercise of common stock options	16					16					16
Exercise of common stock options, Shares				3,000
Restricted stock awards, Shares				172,000
Common stock withholding for employee tax obligations	(494)					(494)					(494)
Common stock withholding for employee tax obligations, Shares				(8,000)
Other comprehensive income (loss)	(11,615)							(11,734)			(11,734)			119
Net income (loss)	153,557								153,979		153,979			(422)
Ending Balance at Mar. 31, 2022	1,312,960			$ 3		507,046		(12,493)	811,576		1,306,132			6,828
Ending Balance, Shares at Mar. 31, 2022				30,327,000
Beginning Balance at Dec. 31, 2021	$ 1,165,880			$ 3		501,908		(759)	657,597		1,158,749			7,131
Beginning Balance, Shares at Dec. 31, 2021	30,160,000			30,160,000
Repurchase of common stock	$ (45,300)
Repurchase of common stock, Shares	(995,000)
Net income (loss)	$ 165,999
Ending Balance at Sep. 30, 2022	$ 1,281,397			$ 3		477,814		(25,602)	824,832		1,277,047			4,350
Ending Balance, Shares at Sep. 30, 2022	30,677,000			29,681,000
Beginning Balance at Mar. 31, 2022	$ 1,312,960			$ 3		507,046		(12,493)	811,576		1,306,132			6,828
Beginning Balance, Shares at Mar. 31, 2022				30,327,000
Equity-based compensation	8,030					8,030					8,030
Exercise of common stock options	3					3					3
Exercise of common stock options, Shares				1,000
Restricted stock awards, Shares				161,000
Common stock withholding for employee tax obligations	(436)					(436)					(436)
Common stock withholding for employee tax obligations, Shares				(8,000)
Repurchase of common stock	(10,577)					(10,577)					(10,577)
Repurchase of common stock, Shares				(215,000)
Other comprehensive income (loss)	(10,346)							(9,924)			(9,924)			(422)
Net income (loss)	11,099								11,537		11,537			(438)
Ending Balance at Jun. 30, 2022	1,310,733			$ 3		504,066		(22,417)	823,113		1,304,765			5,968
Ending Balance, Shares at Jun. 30, 2022				30,266,000
Equity-based compensation	8,972					8,972					8,972
Restricted stock awards, Shares				203,000
Common stock withholding for employee tax obligations	(522)					(522)					(522)
Common stock withholding for employee tax obligations, Shares				(8,000)
Repurchase of common stock	$ (34,702)					(34,702)					(34,702)
Repurchase of common stock, Shares	(780,000)			(780,000)
Other comprehensive income (loss)	$ (4,427)							(3,185)			(3,185)			(1,242)
Net income (loss)	1,343								1,719		1,719			(376)
Ending Balance at Sep. 30, 2022	$ 1,281,397			$ 3		$ 477,814		$ (25,602)	$ 824,832		$ 1,277,047			$ 4,350
Ending Balance, Shares at Sep. 30, 2022	30,677,000			29,681,000

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity (unaudited) (Parenthetical) - $ / shares	Jun. 30, 2021	Mar. 31, 2021
November 2020 Equity Distribution Agreement
Selling price per share	$ 73.75	$ 52

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flow from operating activities:
Net income from consolidated operations	$ 165,999,000	$ 402,562,000
Adjustments to reconcile net income to net cash provided by operating activities:
Equity-based compensation	22,618,000	10,862,000
Depreciation and amortization	22,860,000	7,513,000
Provision for credit losses	25,256,000	4,107,000
Noncash lease expense	3,311,000	682,000
Loss on disposal of fixed asset	300,000	779,000
Amortization of premium of marketable securities	4,230,000	5,490,000
Deferred taxes	(4,934,000)	(6,574,000)
Unrecognized tax benefits	1,101,000	157,000
Net loss on marketable securities	626,000	595,000
Gain on equity method investment		(3,734,000)
Other	(23,000)	(22,000)
Changes in operating assets and liabilities:
Trade accounts receivable	24,214,000	65,003,000
Other current and long-term assets	3,722,000	(2,086,000)
Accounts payable	(32,331,000)	(9,002,000)
Income tax payable	(400,000)	(35,444,000)
Accrued liabilities and other liabilities	(12,905,000)	21,252,000
Operating and finance lease liabilities	(3,331,000)	(649,000)
Net cash provided by operating activities	220,313,000	461,491,000
Cash flow from investing activities:
Purchase of marketable securities	(257,267,000)	(523,939,000)
Acquisition of businesses, net of cash acquired	(137,755,000)	(61,868,000)
Purchase of preferred stock of privately held company	(15,000,000)
Purchases of fixed assets	(14,053,000)	(17,829,000)
Contingent consideration payout related to a business acquisition	(10,000,000)
Purchase of redeemable preferred stock		(20,000,000)
Proceeds from sale of fixed assets	240,000	22,000
Maturities of marketable securities	131,713,000	61,516,000
Proceeds from sale of marketable securities	133,407,000	155,809,000
Net cash used in investing activities	(168,715,000)	(406,289,000)
Cash flow from financing activities:
Repurchase of common stock	(45,279,000)
Common stock withholding for employee tax obligations	(1,452,000)	(3,467,000)
Repayment of notes payable	(367,000)
Principal paid for finance lease	(469,000)	(3,000)
Proceeds from exercise of stock options	19,000	85,000
Proceeds from public offerings of common stock, net of issuance costs		75,626,000
Proceeds from noncontrolling interest		10,000
Net cash (used in) provided by financing activities	(47,548,000)	72,251,000
Effect of exchange rate changes on cash and cash equivalents	(174,000)	(2,000)
Net increase in cash and cash equivalents	3,876,000	127,451,000
Cash and cash equivalents at beginning of period	164,894,000	87,426,000
Cash and cash equivalents at end of period	168,770,000	214,877,000
Supplemental disclosures of cash flow information:
Income taxes paid	56,181,000	169,540,000
Supplemental disclosures of non-cash investing and financing activities:
Purchases of marketable securities in other current liabilities	12,905,000	20,092,000
Contingent consideration for business acquisition included in other current liabilities		8,500,000
Purchases of fixed assets in accounts payable	1,690,000	2,279,000
Purchases of fixed assets in notes payable	3,833,000
Operating lease right-of-use assets obtained in exchange for lease liabilities	52,000	1,706,000
Finance lease right-of-use assets obtained in exchange for lease liabilities	573,000
Operating lease right-of-use assets reduced due to lease modification and termination	$ 66,000	$ 399,000

Overview and Basis of Presentat

Overview and Basis of Presentation	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Overview and Basis of Presentation	Note 1. Overview and Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. These financial statements include the assets, liabilities, revenues and expenses of all subsidiaries and entities in which the Company has a controlling financial interest or is deemed to be the primary beneficiary. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (i) the power to direct the economically significant activities of the entity and (ii) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. The Company uses the equity method to account for its investments in entities that it does not control, but in which it has the ability to exercise significant influence over operating and financial policies. All significant intercompany accounts and transactions are eliminated from the accompanying condensed consolidated financial statements. Nature of the Business Fulgent Genetics, Inc., together with its subsidiaries and affiliated professional corporations, or PCs, collectively referred to as the Company, unless otherwise noted or the context otherwise requires, is a technology company offering large-scale COVID-19 testing services, molecular diagnostic testing services and comprehensive genetic testing designed to provide physicians with clinically actionable diagnostic information to improve the quality of patient care. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs. To this end, the Company has developed a proprietary technology platform allowing it to offer a broad and flexible test menu and to continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing, or NGS, with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels that can be tailored to meet specific customer needs. Unaudited Interim Financial Information The accompanying unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company’s audited consolidated financial statements as of and for the fiscal year ended December 31, 2021, which are included in the Company’s annual report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on February 28, 2022, or the 2021 Annual Report, and, in the opinion of management, include all adjustments, which are normal and recurring in nature, necessary for a fair presentation of the Company’s financial position and results of operations. Operating results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or any other period. The accompanying Condensed Consolidated Balance Sheet as of December 31, 2021 has been derived from the Company’s audited consolidated financial statements at that date but does not include all of the disclosures required by U.S. GAAP. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the 2021 Annual Report, including the notes thereto.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies See the summary of the Company’s significant accounting policies set forth in the notes to its consolidated financial statements included in the 2021 Annual Report. Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting periods. These estimates, judgments and assumptions are based on historical data and experience available at the date of the accompanying condensed consolidated financial statements, as well as various other factors management believes to be reasonable under the circumstances, including but not limited to the potential impacts arising from the recent global pandemic related to COVID-19. As the extent and duration of the impacts from COVID-19 remain unclear, the Company’s estimates and assumptions may evolve as conditions change. Actual results could differ significantly from these estimates. On an on-going basis, management evaluates its estimates, primarily those related to: (i) revenue recognition criteria; (ii) accounts receivable and allowances for credit losses; (iii) the useful lives of fixed assets and intangible assets; (iv) estimates of tax liabilities; and (v) valuation of intangible assets and goodwill. Marketable Securities All marketable debt securities, which consist of corporate debt securities, municipal bonds, U.S. government and agency debt securities, U.S. treasury bills, and Yankee debt securities issued by foreign governments or entities and denominated in U.S. dollars have been classified as “available-for-sale,” and are carried at fair value. Net unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive income (loss) and reported as a separate component of stockholders’ equity until realized. Realized gains and losses on marketable debt securities are included in interest and other income, net, in the accompanying Condensed Consolidated Statements of Income. The cost of any marketable debt securities sold is based on the specific-identification method. The amortized cost of marketable debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on marketable debt securities is included in interest and other income, net. In accordance with the Company’s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities. The Company’s investments in marketable equity securities are measured at fair value with the related gains and losses, realized and unrealized, recognized in interest and other income, net, in the accompanying Condensed Consolidated Statements of Income. The cost of any marketable equity securities sold is based on the specific-identification method. For available-for-sale debt securities, in an unrealized loss, the Company determines whether a credit loss exists. The credit loss is estimated by considering available information relevant to the collectability of the security and information about past events, current conditions, and reasonable and supportable forecasts. The Company compares the present value of cash flows expected to be collected from the security with the amortized cost basis of the security. If the present value of cash flows to be collected is less than the amortized basis of the security, a credit loss exists, and any credit loss is recorded as a charge to interest and other income, net, not to exceed the amount of the unrealized loss. If the Company has an intent to sell, or if it is more likely than not that the Company will be required to sell a debt security in an unrealized loss position before recovery of its amortized cost basis, the Company will write down the security to its fair value and record the corresponding charge as a component of interest and other income, net. Trade Accounts Receivable and Allowance for Credit Losses Trade accounts receivable are stated at the amount the Company expects to collect. The Company maintains an allowance for credit losses for expected uncollectible trade accounts receivable, which is recorded as an offset to trade accounts receivable, and changes in allowance for credit losses are classified as a general and administrative expense in the accompanying Condensed Consolidated Statements of Income. The Company assesses collectability by reviewing trade accounts receivable on a collective basis where similar risk characteristics exist and on an individual basis when it identifies specific customers that have deterioration in credit quality such that they may no longer share similar risk characteristics with the other receivables. In determining the amount of the allowance for credit losses, the Company uses a probability-of-default and loss given default model, which allows the ability to define a point of default and measure credit losses for receivables that have reached the point of default for purposes of calculating the allowance for credit losses. Loss given default represents the likelihood that a receivable that has reached the point of default will not be collected in full. The Company updates its probability-of-default and loss given default factors annually to incorporate the most recent historical data and adjusts the quantitative portion of the reserve through its qualitative reserve overlay. The Company looks at qualitative factors such as general economic conditions in determining expected credit losses. During the three and nine months ended September 30, 2022, the Company recorded $ 6.5 million and $ 25.3 million of provision for credit losses for trade accounts receivable, respectively. During the three and nine months ended September 30, 2021, the Company recorded $ 848,000 and $ 4.1 million of provision for credit losses for trade accounts receivable, respectively. Redeemable Preferred Stock Investment The redeemable preferred stock investment of $ 11.2 million as of September 30, 2022 represents the fair value of redeemable preferred stock of a private company that the Company purchased in July 2021. The investment is classified as available-for-sale debt securities. The fair value of available-for-sale debt security is included in the Consolidated Statement of Balance Sheets. Unrealized losses of $ 748,000 and $ 10.7 million were excluded from earnings and reported in other comprehensive loss for the three and nine months ended September 30, 2022. There was no unrealized gain or loss in the three and nine months ended September 30, 2021. Since the Company intends on holding the preferred stock, and the preferred stock is not redeemable until July 2027 , the investment is recorded as a long-term investment. Foreign Currency Translation and Foreign Currency Transactions The Company translates the assets and liabilities of its non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recognized in foreign currency translation included in accumulated other comprehensive income (loss) in the accompanying Condensed Consolidated Statements of Stockholders’ Equity. Loss from these translations were $ 1.9 million and $ 3.7 million in the three and nine months ended September 30, 2022, respectively. Loss from these translations were not significant in the three and nine months ended September 30, 2021. The Company and its subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period, whereas reagents and supplies, property and nonmonetary assets and liabilities are measured at historical rates. Losses from these remeasurements were not significant in the three and nine months ended September 30, 2022 and 2021. Comprehensive Income (Loss) Comprehensive income (loss) is comprised of net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) consists of net unrealized gain or loss on available-for-sale d ebt securities, net of tax, and foreign currency translation adjustments from the Company's subsidiaries not using the U.S. dollar as their functional currency. Reclassifications from other comprehensive income (loss) to net earnings were not significant in the three and nine months ended September 30, 2022 and 2021. The tax effects related to net unrealized loss on available-for-sale debt securities were $ 3.6 million and $ 9.4 million in the three and nine months ended September 30, 2022, respectively. The tax effects were no t significant in the three and nine months ended September 30, 2021 . Leases The Company determines if an arrangement is a lease at inception by evaluating whether the arrangement conveys the right to use an identified asset and whether the Company obtains substantially all of the economic benefits from and has the ability to direct the use of the asset. Operating and finance lease right-of-use assets, or ROU assets, short-term lease liabilities, and long-term lease liabilities are included in other long-term assets, accrued liabilities, and other long-term liabilities, respectively, in the accompanying Condensed Consolidated Balance Sheets. Lease ROU assets represent the Company’s right to use an underlying asset for the lease term. Lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term, including options to extend the lease when it is reasonably certain that the Company will exercise that option. The Company uses its incremental borrowing rate based on the information available at the commencement date, including inquiries with its bank, in determining the present value of lease payments since its leases do not provide an implicit rate. Lease ROU assets consist of initial measurement of lease liabilities, any lease payments made to lessor on or before the lease commencement date, minus any lease incentive received, and any initial direct costs incurred by the Company. Operating lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance lease, ROU assets are amortized on a straight-line basis from the commencement date to the earlier of the end of useful life of the ROU assets or the end of the lease term. Amortization of ROU assets and interest on the lease liability for finance leases are included as charges to the accompanying Condensed Consolidated Statements of Income. Lease ROU assets and liabilities arising from business combinations are recognized and measured at the acquisition dates as if an acquired lease were a new lease at the date of acquisition using the Company’s incremental borrowing rate unless the discount rate is implicit in the lease. The Company elects to not to recognize assets or liabilities as of the acquisition dates for leases that, on the acquisition dates, have a remaining lease term of 12 months or less. The Company also retains the acquirees’ classification of the leases if there are no modifications as part of the business combinations. The Company leases and subleases out space in buildings it owns or leases to third-party tenants or subtenants under noncancelable operating leases. The Company recognizes lease payments as income over the lease terms on a straight-line basis and recognizes variable lease payments as income in the period in which the changes in facts and circumstances on which the variable lease payments are based occur. The net rental income is included in the interest and other income, net, in the accompanying Condensed Consolidated Statements of Income. Concentration of Customers In certain periods, a small number of customers have accounted for a significant portion of the Company’s revenue. After aggregating customers that are under common control or affiliation, one customer contributed 13 % and 21 % of the Company's revenue for the three and nine months ended September 30, 2022, respectively. Two customers contributed 31 % and 11 %, respectively, of the Company’s revenue for the three months ended September 30, 2021, and one customer contributed 26 % of the Company’s revenue for the nine months ended September 30, 2021. No single customer comprised 10 % or more of total accounts receivable as of September 30, 2022 and December 31, 2021. Disaggregation of Revenue The Company classifies its customers into three payor types: (i) Insurance, including claim reimbursement from the U.S. Health Resources and Services Administration, or H RSA, for uninsured individuals, (ii) Institutional customers, including hospitals, medical institutions, other laboratories, governmental bodies, municipalities and large corporations, or (iii) Patients who pay directly, as the Company believes this best depicts how the nature, amount, timing, and uncertainty of its revenue and cash flows are affected by economic factors. The following table summarizes revenue from contracts with customers by payor type for the three and nine months ended September 30, 2022 and 2021. Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (in thousands) Testing Services by payor Insurance $ 63,030 $ 143,276 $ 337,497 $ 400,354 Institutional customers 42,280 84,401 212,980 339,572 Patients 345 191 787 987 Total Revenue $ 105,655 $ 227,868 $ 551,264 $ 740,913 The insurance revenue category above includes zero and $ 81.9 million for the three months ended September 30, 2022 and 2021, respectively, and $ 92.7 million and $ 231.5 million for the nine months ended September 30, 2022 and 2021, respectively, for services related to claims covered by the HRSA COVID-19 Uninsured Program. The HRSA program stopped accepting claims at 11:59 p.m. on March 22, 2022. There was no material variable consideration recognized in the current period that relates to performance obligations that were completed in the prior period. Collection of the Company’s net revenues from insurers is normally a function of providing complete and correct billing information within the various filing deadlines. Provided the Company has billed insurers accurately with complete information prior to the established filing deadline, there has historically been little to no credit risk. If there has been a delay in billing, the Company determines if the amounts in question will likely go past the filing deadline, and if so, the Company will reserve accordingly for the billing. Contract Balances Receivables from contracts with customers - Receivables from contracts with customers are included within trade accounts receivable on the Condensed Consolidated Balance Sheets. Net receivable from Insurance and Institutional customers represented 78 % and 22 %, respectively, as of September 30, 2022. Net receivable from Insurance and Institutional customers represented 47 % and 53 %, respectively, as of December 31, 2021. Contracts assets and liabilities - Contract assets from contracts with customers associated with contract execution and certain costs to fulfill a contract are included in other current assets in the accompanying Condensed Consolidated Balance Sheets. Contract liabilities are recorded when the Company receives payment prior to completing its obligation to transfer goods or services to a customer. Contract liabilities are included in the Condensed Consolidated Balance Sheets. Revenues of $ 8.5 million and $ 5.7 million were recognized for the three months ended September 30, 2022 and 2021, respectively, and $ 14.4 million and $ 26.4 million were recognized for the nine months ended September 30, 2022 and 2021, respectively, related to contract liabilities at the beginning of the respective periods. Reagents and Supplies The Company maintains reagents and other consumables primarily used in sample collections and testing which are valued at the lower of cost or net realizable value. Cost is determined using actual costs on a first-in, first-out basis. The reagents and supplies were included in other current assets in the accompanying Condensed Consolidated Balance Sheets. Customer Deposit Customer deposit in the accompanying Condensed Consolidated Balance Sheets consists of payments received from customers in excess of their outstanding trade accounts receivable balances or amounts customers believe were potentially paid in error. These deposits will be offset against future testing receivables or refunded to the customers. The largest deposit as of September 30, 2022 was recorded in the amount of $ 16.0 million. Business Combination The Company uses the acquisition method of accounting and allocates the fair value of purchase consideration to the assets acquired and liabilities assumed from an acquiree based on their respective fair values as of the acquisition date. The excess of the fair value of purchase consideration over the fair value of these assets acquired and liabilities assumed is recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions, especially with respect to intangible assets. Critical estimates in valuing intangible assets include, but are not limited to, expected future cash flows, which includes consideration of future growth and margins, future changes in technology, expected cost and time to develop in-process research and development, brand awareness and discount rates. Fair value estimates are based on the assumptions that management believes a market participant would use in pricing the asset or liability. Goodwill Goodwill is not amortized but is subject to impairment tests on an annual basis, or more frequently if indicators of potential impairment exist, and goodwill is written down when it is determined to be impaired. The Company typically performs an annual impairment review in the fourth quarter of each fiscal year unless one had been performed previously within the past 12 months and compares the fair value of the reporting unit in which the goodwill resides to its carrying value. Restructuring Costs Restructuring costs represent one-time employee termination benefits provided to employees associated with a newly acquired entity that were involuntarily terminated. A plan of termination was approved and authorized by management in the second quarter of 2022. The plan identified specific employees to be terminated and established terms of benefits those employees would receive upon termination. Total restructuring costs incurred in the three and nine months ended September 30, 2022 were $ 105,000 and $ 3.0 million , respectively, and payable balance as of September 30, 2022 was $ 2.0 million, which is included in accrued liabilities in the accompanying Condensed Consolidated Balance Sheets. No additional costs are expected to be incurred under the plan of termination, and the payable balance is expected to be paid off by August 2023 . There were no such costs in the prior fiscal year. Recent Accounting Pronouncements The Company evaluates all Accounting Standards Updates, or ASUs, issued by the Financial Accounting Standards Board, or FASB, for consideration of their applicability. ASUs not included in the Company’s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company’s condensed consolidated financial statements.

Equity and Debt Securities

Equity and Debt Securities	9 Months Ended
	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Equity and Debt Securities	Note 3. Equity and Debt Securities The Company’s equity and debt securities consisted of the following: September 30, 2022 Amortized Unrealized Unrealized Aggregate (in thousands) Equity securities: Long-term Preferred stock of privately held company $ 15,000 $ — $ — 15,000 Total equity securities 15,000 — — 15,000 Available-for-sale debt securities Short-term U.S. government debt securities 181,333 — ( 2,824 ) 178,509 Corporate debt securities 124,181 — ( 2,120 ) 122,061 Money market accounts 87,382 — — 87,382 U.S. treasury bills 72,522 6 ( 285 ) 72,243 U.S. agency debt securities 32,505 — ( 483 ) 32,022 Municipal bonds 8,058 — ( 123 ) 7,935 Yankee debt securities 7,582 — ( 147 ) 7,435 Less: Cash equivalents ( 105,292 ) ( 5 ) — ( 105,297 ) Total debt securities due within 1 year 408,271 1 ( 5,982 ) 402,290 After 1 year through 5 years U.S. government debt securities 181,464 — ( 8,261 ) 173,203 Corporate debt securities 114,848 — ( 6,584 ) 108,264 U.S. agency debt securities 52,230 — ( 3,467 ) 48,763 Municipal bonds 12,929 — ( 382 ) 12,547 Yankee debt securities 753 — ( 100 ) 653 Redeemable preferred stock investment 20,000 — ( 8,767 ) 11,233 Total debt securities due after 1 year through 5 years 382,224 — ( 27,561 ) 354,663 After 5 years through 10 years Municipal bonds 3,654 — ( 138 ) 3,516 Total debt securities due after 5 years through 10 years 3,654 — ( 138 ) 3,516 Total available-for-sale debt securities 794,149 1 ( 33,681 ) 760,469 Total equity and debt securities $ 809,149 $ 1 $ ( 33,681 ) $ 775,469 December 31, 2021 Amortized Unrealized Unrealized Aggregate (in thousands) Equity securities: Short-term Bond funds $ 99,314 $ — $ ( 515 ) $ 98,799 Exchange traded funds 35,174 — ( 174 ) 35,000 Total equity securities 134,488 — ( 689 ) 133,799 Available-for-sale debt securities Short-term Corporate debt securities 92,116 24 ( 148 ) 91,992 Money market accounts 77,067 — — 77,067 U.S. government debt securities 51,318 — ( 81 ) 51,237 Municipal bonds 4,980 — ( 12 ) 4,968 Yankee debt securities 3,615 — ( 6 ) 3,609 Less: Cash equivalents ( 77,067 ) — — ( 77,067 ) Total debt securities due within 1 year 152,029 24 ( 247 ) 151,806 After 1 year through 5 years Corporate debt securities 242,421 29 ( 1,913 ) 240,537 U.S. Government debt securities 147,699 7 ( 786 ) 146,920 U.S. agency debt securities 70,069 — ( 535 ) 69,534 Municipal bonds 11,920 13 ( 11 ) 11,922 Yankee debt securities 8,633 — ( 89 ) 8,544 Total debt securities due after 1 year through 5 years 480,742 49 ( 3,334 ) 477,457 After 5 years through 10 years Municipal bonds 7,633 — ( 43 ) 7,590 Redeemable preferred stock investment 20,000 1,965 — 21,965 Total debt securities due after 5 years through 10 years 27,633 1,965 ( 43 ) 29,555 Total available-for-sale debt securities 660,404 2,038 ( 3,624 ) 658,818 Total equity and debt securities $ 794,892 $ 2,038 $ ( 4,313 ) $ 792,617 Gross unrealized losses on the Company’s equity and debt securities were $ 33.7 million as of September 30, 2022. Gross unrealized losses on the Company’s equity and debt securities were $ 4.3 million as of December 31, 2021. The Company did not recognize any credit losses during the three and nine months ended September 30, 2022 and 2021. The Company’s securities of $ 489.7 million are used as collateral for an outstanding margin account borrowing. As of September 30, 2022, the Company had an outstanding borrowing of $ 15.0 million under its margin account. Margin account borrowings were used for the purchase of real property located in El Monte, California in 2020.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 4. Fair Value Measurements The authoritative guidance on fair value measurements establishes a framework with respect to measuring assets and liabilities at fair value on a recurring basis and non-recurring basis. Under the framework, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, as of the measurement date. The framework also establishes a three-tier hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability and are developed based on the best information available in the circumstances. The hierarchy consists of the following three levels: Level 1: Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access at the measurement date. Level 2: Inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3: Inputs are unobservable for the asset or liability. The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the above three-tier fair value hierarchy: September 30, 2022 Total Level 1 Level 2 Level 3 (in thousands) Equity securities, debt securities and cash equivalents: U.S. government debt securities $ 351,712 $ — $ 351,712 $ — Corporate debt securities 230,325 — 230,325 — Money market accounts 87,382 87,382 — — U.S. agency debt securities 80,785 — 80,785 — U.S. treasury bills 72,243 72,243 — — Municipal bonds 23,998 — 23,998 — Preferred stock of privately held company 15,000 — — 15,000 Redeemable preferred stock investment 11,233 — — 11,233 Yankee debt securities 8,088 — 8,088 — Total equity securities, debt securities and cash equivalents $ 880,766 $ 159,625 $ 694,908 $ 26,233 December 31, 2021 Total Level 1 Level 2 Level 3 (in thousands) Equity securities, debt securities and cash equivalents: Corporate debt securities $ 332,529 $ — $ 332,529 $ — U.S. government debt securities 198,157 — 198,157 — Bond funds 98,799 98,799 — — U.S. agency debt securities 69,534 — 69,534 — Exchange traded funds 35,000 35,000 — — Municipal bonds 24,480 — 24,480 — Yankee debt securities 12,153 — 12,153 — Redeemable preferred stock investment 21,965 — — 21,965 Money market accounts 77,067 77,067 — — Total equity securities, debt securities and cash equivalents $ 869,684 $ 210,866 $ 636,853 $ 21,965 The Company’s Level 1 assets include bond funds, exchange traded funds, U.S. treasury bills, and money market instruments and are valued based upon observable market prices. Level 2 assets consist of U.S. government and U.S. agency debt securities, municipal bonds, corporate debt securities and Yankee debt securities. Level 2 securities are valued based upon observable inputs that include reported trades, broker/dealer quotes, bids and offers. As of September 30, 2022, the Company had $ 15.0 million of preferred stock of a privately held company, which was included in other long-term assets in the accompanying Condensed Consolidated Balance Sheets, and $ 11.2 million of redeemable preferred stock of a private company that were measured using unobservable (Level 3) inputs. The fair value of redeemable preferred stock as of September 30, 2022 and December 31, 2021 was based on valuation performed by a third-party valuation company utilizing the guideline public company method under market approach and the discounted cash flow method under income approach. For the value of the investment in private equity securities, the Company elected to measure it at cost minus impairment, as the preferred stock of the privately held company did not have a readily determinable fair value, and no impairment loss was recorded as of September 30, 2022. There were no transfers between fair value measurement levels during the three and nine months ended September 30, 2022 and 2021.

Fixed Assets

Fixed Assets	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Fixed Assets	Note 5. Fixed Assets Major classes of fixed assets consisted of the following: September 30, December 31, Useful Lives 2022 2021 (in thousands) Medical lab equipment 1 to 12 Years $ 48,570 $ 35,930 Leasehold improvements Shorter of lease term or estimated useful life 11,175 4,003 Computer hardware 1 to 5 Years 6,906 5,661 Computer software 1 to 5 Years 6,793 1,408 Building 39 Years 6,731 6,731 Aircraft 7 Years 6,503 6,503 Building improvements 6 months to 39 Years 5,749 3,936 Furniture and fixtures 1 to 5 Years 4,160 2,255 Automobile 2 to 7 Years 811 825 Land improvements 5 to 15 Years 616 403 General equipment 3 to 5 Years 44 44 Land 7,500 7,500 Assets not yet placed in service 12,215 6,718 Total 117,773 81,917 Less: Accumulated depreciation ( 35,966 ) ( 19,630 ) Fixed assets, net $ 81,807 $ 62,287 Depreciation expenses on fixed assets totaled $ 7.6 million and $ 2.5 million for the three months ended September 30, 2022 and 2021, respectively, and $ 17.9 million and $ 6.7 million for the nine months ended September 30, 2022 and 2021, respectively.

Other Balance Sheet Accounts

Other Balance Sheet Accounts	9 Months Ended
	Sep. 30, 2022
Balance Sheet Related Disclosures [Abstract]
Other Balance Sheet Accounts	Note 6. Ot her Balance Sheet Accounts Other current assets consisted of the following: September 30, December 31, 2022 2021 (in thousands) Prepaid expenses $ 8,399 $ 4,244 Reagents and supplies 7,509 12,206 Marketable securities interest receivable 2,733 2,743 Prepaid income taxes 2,055 1,716 Other receivable 699 1,403 Contract assets — 237 Total $ 21,395 $ 22,549 Reagents and supplies include reagents and consumables used for COVID-19 testing and genetics testing and collection kits for COVID-19 testing. Other current liabilities consisted of the following: September 30, December 31, 2022 2021 (in thousands) Payable to a broker $ 12,905 $ — Other 716 680 Total $ 13,621 $ 680 The payable to a broker was for marketable securities purchased before the period-end that did not settle until after period-end.

Reporting Segment and Geographi

Reporting Segment and Geographic Information	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Reporting Segment and Geographic Information	Note 7. Reporting Segment and Geographic Information The Company views its operations and manages its business in one reporting segment. Long-lived assets were primarily located in the United States as of September 30, 2022 and December 31, 2021. Revenue by region during the three and nine months ended September 30, 2022 and 2021 were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (in thousands) Revenue: United States $ 101,515 $ 223,685 $ 540,801 $ 731,084 Foreign 4,140 4,183 10,463 9,829 Total $ 105,655 $ 227,868 $ 551,264 $ 740,913

Debt, Commitments and Contingen

Debt, Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Debt Commitments And Contingencies Disclosure [Abstract]
Debt, Commitments and Contingencies	Note 8. Debt, Commitments and Contingencies Debt As of September 30, 2022, the Company had an outstanding borrowing of $ 15.0 million under its margin account with the custodian of the Company’s marketable debt security investment account, Pershing Advisor Solutions, LLC, a BNY Mellon Company. Margin account borrowings were used for the purchase of real property located in El Monte, California in 2020. The securities in the brokerage account were used as collateral for the margin loan. The custodian can issue a margin call at any time. The interest rate on the margin loan was the effective federal funds rate, or EFFR, plus a spread. The EFFR and/or the spread can be changed by BNY Mellon at any time. The interest was 1 % at the time of withdrawal of $ 15.0 million from the margin account, and the interest rate at September 30, 2022 was 3 % . The Company did not make any other withdrawals from the margin account, and the outstanding balance is included in the accompanying Condensed Consolidated Balance Sheets. The related interest expenses for the three and nine months ended September 30, 2022 were $ 105,000 and $ 185,000 , respectively. The related interest expenses for the three and nine months ended September 30, 2021 were $ 30,000 and $ 88,000 , respectively. Notes payable as of September 30, 2022 consisted of $ 3.8 million of notes payable related to an installment sale contract the Company entered in February 2022 for a building and $ 5.0 million of notes payable to Xilong Scientific Co., or Xilong Scientific, by Fujian Fujun Gene Biotech Co., Ltd., or FF Gene Biotech. The notes payable related to the installment sale are due in February 2030, and the interest rate is 1.08 %. The current portion and noncurrent portion are $ 461,000 and $ 3.4 million , respectively, and the noncurrent portion is included in the other long-term liabilities in the accompanying Condensed Consolidated Balance Sheets. The notes payable to Xilong Scientific are due on December 31, 2022, and the interest rate on the loan is 4.97 %. The related interest expenses for the three and nine months ended September 30, 2022 were $ 75,000 and $ 231,000 , respectively. The related interest expenses for the three and nine months ended September 30, 2021 were $ 74,000 . The Company did no t have the installment sale contract in 2021. Operating Leases See Note 9, Leases , for further information. Purchase Obligations As of September 30, 2022, the Company had non-cancelable purchase obligations of $ 15.8 million , of which, $ 5.5 million for computer software and hardware, $ 5.2 million for reagents and other supplies, $ 3.2 million for services, and $ 1.4 million for medical lab equipment are payable within twelve months, and $ 485,000 for services is payable within the next twenty-four months. Contingencies From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. In the opinion of management, the outcome of these matters would not have a material effect on the Company’s condensed consolidated financial position, results of operations or cash flows. The Company has received a Civil Investigative Demand, or CID, issued by the U.S. Department of Justice pursuant to the False Claims Act related to its investigation of allegations of medically unnecessary laboratory testing, improper billing for laboratory testing, and remuneration received or provided in violation of the Anti-Kickback Statute and the Stark Law. This CID requests information and records relating to certain of the Company’s customers named in the CID, which represent a small portion of the Company’s revenues. The Company is fully cooperating with the U.S. Department of Justice to promptly respond to the requests for information in this CID, and does not presently expect this CID or resulting investigation to have a material adverse impact. However, the Company cannot predict when the investigation will be resolved, the outcome of the investigation or its potential impact, which may ultimately be greater than what the Company currently expects.

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Leases	Note 9. Leases Lessee The Company is party as a lessee to various non-cancelable operating leases with varying terms through March 2028 primarily for laboratory and office space and equipment. The Company has options to renew some of these leases after their expirations. On a lease-by-lease basis, the Company considers such options, which may be elected at the Company’s sole discretion, in determining the lease term. The Company also has four finance leases for lab equipment through December 2026, one of which was acquired in a recent business combination. The Company retained acquirees’ classification of its leases. The Company does not have any leases with variable lease payments. The Company’s operating lease agreements do not contain any residual value guarantees, material restrictive covenants, bargain purchase options or asset retirement obligations. The Company’s headquarters are located in Temple City, California, which is comprised of various corporate offices and a laboratory certified under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, accredited by the College of American Pathologists, or CAP, and licensed by the State of California Department of Public Health. Other CLIA-certified laboratories are located in Houston, Texas; Alpharetta, Georgia; Phoenix, Arizona; New York, New York; Irving, Texas; and Needham, Massachusetts. Additional offices are located in Atlanta, Georgia and are used for certain report generation functions. The operating and finance lease right-of-use asset, short-term lease liabilities, and long-term lease liabilities as of September 30, 2022 and December 31, 2021 were as follows: September 30, December 31, 2022 2021 (in thousands) Operating lease ROU asset, net $ 16,363 $ 7,141 Operating lease liabilities, short term $ 6,184 $ 1,842 Operating lease liabilities, long term $ 10,282 $ 5,344 Finance lease ROU asset, net $ 3,010 $ 1,735 Finance lease liabilities, short term $ 927 $ 332 Finance lease liabilities, long term $ 2,050 $ 1,398 The following was operating and finance lease expense: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (in thousands) Operating lease cost $ 1,770 $ 429 $ 3,674 $ 730 Finance lease cost: Amortization of ROU assets 225 3 490 3 Interest on lease liabilities 31 — 66 — Short-term lease cost 112 53 1,042 245 Total lease cost $ 2,138 $ 485 $ 5,272 $ 978 Supplemental information related to operating leases and finance lease was the following: September 30, 2022 Weighted average remaining lease term - operating leases 3.39 years Weighted average discount rate - operating leases 3.82 % Weighted average remaining lease term -finance lease 3.33 years Weighted average discount rate - finance lease 3.98 % The following is a maturity analysis of operating and finance lease liabilities using undiscounted cash flows on an annual basis with renewal periods included: Operating Leases Finance Lease (in thousands) Year Ending December 31, 2022 (remaining 3 months) $ 1,717 $ 207 2023 6,579 1,033 2024 4,063 1,026 2025 2,112 544 2026 1,521 366 2027 1,360 — Thereafter 217 — Total lease payments 17,569 3,176 Less imputed interest ( 1,103 ) ( 199 ) Total $ 16,466 $ 2,977 Lessor The Company leases out space in buildings it owns and leases to third-party tenants under noncancelable operating leases. As of September 30, 2022, the remaining lease terms left range from 3 months to 16 months, including renewal options and may include rent escalation clauses. Lease income primarily represents fixed lease payments from tenants recognized on a straight-line basis over the application lease term. Variable lease income represents tenant payments for real estate taxes, insurance and maintenance. The lease income was included in interest and other income, net, in the accompanying Condensed Consolidated Statements of Income. Total lease income was as follows: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (in thousands) Lease income $ 48 $ 78 $ 229 $ 315 Variable lease income — 1 12 6 Total lease income $ 48 $ 79 $ 241 $ 321 Future fixed lease payments from tenants for all noncancelable operating leases as of September 30, 2022 are as follows: Lease Payments from Tenants (in thousands) Year Ending December 31, 2022 (remaining 3 months) $ 40 2023 93 2024 3 2025 — Total $ 136

Equity-Based Compensation

Equity-Based Compensation	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Equity-Based Compensation	Note 10. Equity-Based Compensation The Company has included equity-based compensation expense as part of cost of revenue and operating expenses in the accompanying Condensed Consolidated Statements of Income as follows: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (in thousands) Cost of revenue $ 2,475 $ 962 $ 6,183 $ 2,328 Research and development 2,687 1,757 7,110 4,461 Selling and marketing 1,243 693 3,148 1,739 General and administrative 2,567 962 6,177 2,334 Total $ 8,972 $ 4,374 $ 22,618 $ 10,862

Provision for Income Taxes

Provision for Income Taxes	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Provision for Income Taxes	Note 11. Provision for Income Taxes The effective tax rate used for interim periods is the estimated annual effective consolidated tax rate, based on the current estimate of full year results, except that taxes related to specific events, if any, are recorded in the interim period in which they occur. The annual effective tax rate is based upon several significant estimates and judgments, including the estimated annual pre-tax income of the Company in each tax jurisdiction in which it operates, and the development of tax planning strategies during the year. In addition, the Company’s tax expense can be impacted by changes in tax rates or laws and other factors that cannot be predicted with certainty. As such, there can be significant volatility in interim tax provisions. The Company recorded consolidated provision for income taxes of $ 414,000 and $ 51.5 million for the three and nine months ended September 30, 2022, respectively, compared with $ 37.5 million and $ 127.6 million for the three and nine months ended September 30, 2021, respectively. The Company’s effective tax rates was 24 % for the three and nine months ended September 30, 2022, respectively, compared with 23 % and 24 % for the three and nine months ended September 30, 2021, respectively. The Company is not currently under examination by any major income tax jurisdiction. During 2022, the statutes of limitations will lapse on the Company's 2018 federal tax year and certain 2017 and 2018 state tax years. The Company does not believe the federal or state statute lapses or any other event will significantly impact the balance of unrecognized tax benefits in the next twelve months. The net balance of unrecognized tax benefits was not material to the interim financial statements for the three and nine months ended September 30, 2022 and 2021.

Income per Share

Income per Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Income per Share	Note 12. Income per Share The following table presents the calculation of basic and diluted income per share for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (in thousands, except per share data) Net income attributable to Fulgent $ 1,719 $ 122,522 $ 167,235 $ 403,025 Weighted-average common shares—outstanding, basic 30,174 29,673 30,256 29,221 Weighted-average common shares—outstanding, diluted 30,867 31,170 31,107 30,906 Net income per common share, basic $ 0.06 $ 4.13 $ 5.53 $ 13.79 Net income per common share, diluted $ 0.06 $ 3.93 $ 5.38 $ 13.04 The following securities have been excluded from the calculation of diluted income per share because their effect would have been anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (in thousands) Options 7 5 10 5 Restricted Stock Units 1,238 241 697 129 The anti-dilutive shares described above were calculated using the treasury stock method.

Related Parties

Related Parties	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Related Parties	Note 13. Related Parties Linda Marsh, who is a member of the Company’s board of directors, is currently the Senior Executive Vice President of AHMC Healthcare Inc., or AHMC. The Company performs genetic testing and other testing services, on an arms-length basis, for AHMC, and the Company recognized $ 299,000 and $ 1.3 million in revenue from AHMC in the three and nine months ended September 30, 2022, respectively. The Company recognized $ 762,000 and $ 2.6 million in revenue in the three and nine months ended September 30, 2021, respectively. As of September 30, 2022 and December 31, 2021, $ 197,000 and $ 556,000 , respectively, was owed to the Company by AHMC, which is included in trade accounts receivable, net, in the accompanying Condensed Consolidated Balance Sheets, in connection with this relationship. The Company and Fulgent Pharma LLC, the Company’s former subsidiary and currently wholly-owned subsidiary of Fulgent Pharma Holdings, Inc., or Fulgent Pharma Holdings, are party to shared services arrangements where research and development, administrative services and office space and equipment are provided between the companies, on an arms-length basis. Until April 2022, Ming Hsieh was the manager and a member of Fulgent Pharma LLC. In April 2022, Fulgent Pharma LLC became a wholly-owned subsidiary of Fulgent Pharma Holdings which was 100 % owned by Ming Hsieh, the Chief Executive Officer and Chairman of the Company’s board of directors, and the Hsieh Family Dynasty Trust, dated January 27, 2010, or the Hsieh Trust, of which Mr. Hsieh is the grantor. Mr. Hsieh and Paul Kim, the Chief Financial Officer and Treasurer of Fulgent Genetics, also served as executive officers of Fulgent Pharma Holdings as its (i) President and Chief Executive Officer and (ii) Treasurer and Secretary, respectively. The cost of research and development services rendered by Fulgent Pharma LLC for the Company was no t significant in the three and nine months ended September 30, 2022. During the three and nine months ended September 30, 2021, the cost of research and development services rendered by Fulgent Pharma LLC for the Company was $ 74,000 and $ 279,000 , respectively. Amounts for services performed by the Company for Fulgent Pharma LLC were no t significant during the three and nine months ended September 30, 2022 and 2021. As of September 30, 2022, $ 66,000 was owed to the Company by Fulgent Pharma LLC, which was included in other current assets in the accompanying Condensed Consolidated Balance Sheets, in connection with these relationships. As of December 31, 2021, $ 679,000 , was owed to Fulgent Pharma LLC by the Company, which was included in other current liabilities in the accompanying Condensed Consolidated Balance Sheets, in connection with these relationships. On November 7, 2022, the Company acquired Fulgent Pharma Holdings. See Note 17, Subsequent Events . Ming Hsieh is the owner of PTJ Associates Inc., or PTJ. PTJ provides flight services to the Company on an arms-length basis. During the three and nine months ended September 30, 2022, the Company incurred zero and $ 235,000 , respectively, in expenses for flights between California and Texas to transport employees and supplies. The Company incurred $ 65,000 and $ 142,000 in expenses for flights between California and Texas to transport employees and supplies in the three and nine months ended September 30, 2021, respectively. As of September 30, 2022 and December 31, 2021, no amount was owed to PTJ by the Company. Ming Hsieh is also on the board of directors and a 20 % owner of ANP Technologies, Inc., or ANP. The Company purchased COVID-19 antigen rapid tests kits from ANP. During the three and nine months ended September 30, 2022, the Company purchased a total of $ 120,000 and $ 280,000 of COVID-19 antigen rapid tests kits, respectively. The Company did no t incur such expense in the three and nine months ended September 30, 2021. As of September 30, 2022 and December 31, 2021, $ 69,000 and zero was owed to ANP by the Company in connection with this relationship.

Goodwill and Acquisition-Relate

Goodwill and Acquisition-Related Intangibles	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Acquisition-Related Intangibles	Note 14. Goodwill and Acquisition-Related Intangibles Summaries of goodwill and intangibles balances assets as of September 30, 2022 and December 31, 2021 were as follows: September 30, December 31, Weighted-Average Amortization Period 2022 2021 (in thousands) Goodwill $ 120,313 $ 50,897 Royalty-free technology 10 Years $ 5,201 $ 5,803 Less: accumulated amortization ( 737 ) ( 387 ) Royalty-free technology, net 4,464 5,416 Customer relationships 13 Years 82,715 28,845 Less: accumulated amortization ( 4,608 ) ( 1,125 ) Customer relationships, net 78,107 27,720 Trade name 8 Years 3,790 1,090 Less: accumulated amortization ( 288 ) ( 45 ) Trade name, net 3,502 1,045 In-place lease intangible assets 5 Years 360 — Less: accumulated amortization ( 29 ) — In-place lease intangible assets, net 331 — Laboratory information system platform 5 Years 1,860 1,860 Less: accumulated amortization ( 434 ) ( 155 ) Laboratory information system platform, net 1,426 1,705 Purchased patent 10 Years 28 31 Less: accumulated amortization ( 5 ) ( 3 ) Purchased patent, net 23 28 Total intangible assets, net $ 87,853 $ 35,914 Changes in the carrying amount of goodwill for the nine months ended September 30, 2022 are as follows: Amounts (in thousands) Balance as of January 1, 2022 Goodwill $ 50,897 Accumulated impairment losses — 50,897 Goodwill acquired during year 71,844 Net exchange differences ( 2,428 ) Balance as of September 30, 2022 Goodwill 120,313 Accumulated impairment losses — $ 120,313 Based on the carrying value of intangible assets recorded as of September 30, 2022, and assuming no subsequent impairment of the underlying assets, the annual amortization expense for intangible assets is expected to be as follows: Amounts (in thousands) Year Ending December 31, 2022 (remaining 3 months) $ 1,960 2023 7,841 2024 7,841 2025 7,841 2026 7,536 2027 7,209 Thereafter 47,625 Total $ 87,853

Business Combinations

Business Combinations	9 Months Ended
	Sep. 30, 2022
Business Combinations [Abstract]
Business Combinations	Note 15. Business Combinations Inform Diagnostics On April 26, 2022, the Company completed the acquisition of 100 % of the outstanding equity of Symphony Buyer, Inc., or Inform Diagnostics, a leading national independent pathology laboratory based in Irving, Texas. Under the terms of the Agreement and Plan of Merger, dated April 16, 2022, or the Inform Merger Agreement, the total purchase price payable to the securityholders of Symphony Buyer, Inc. was approximately $ 170 million, as adjusted for closing cash, closing indebtedness, closing working capital, closing transaction expenses and other transaction matters. With the addition of Inform Diagnostics, the Company will further expand the Company’s genomic testing footprint and extend its test menu into breast pathology, gastrointestinal pathology, dermatopathology, urologic pathology, neuropathology, and hematopathology. The financial results of Inform Diagnostics are included in the condensed consolidated financial statements from the date of acquisition. The Company all ocated the purchase price to tangible and identified intangible assets acquired and liabilities assumed based on estimated fair values. During the three months ended September 30, 2022, the Company updated the purchase price allocation based on the finalized valuation of Inform Diagnostic's intangible and fixed assets. The following tables summarizes the consideration paid and the updated amounts of the assets acquired and liabilities assumed recognized at the acquisition date: Amounts (in thousands) Considerations Cash, net of cash received $ 137,755 Recognized amounts of identifiable assets acquired and liabilities assumed Net working capital $ ( 15,024 ) Fixed assets 20,242 ROU assets - operating 12,653 ROU assets - finance 1,183 Deferred tax assets 3,410 Other long-term assets 4,711 Identifiable intangible assets 57,060 Operating lease liabilities ( 12,653 ) Finance lease liabilities ( 1,183 ) Income tax payable ( 40 ) Other long-term liabilities ( 4,449 ) Recognized amounts of identifiable assets acquired and liabilities assumed, net 65,910 Goodwill 71,845 Total $ 137,755 The goodwill of $ 71.8 million arising from the acquisition is attributed to the expected synergies, assembled workforce, other benefits that will be potentially generated from the combination and deferred tax. The goodwill recognized is not deductible for tax purposes. The identified intangible assets acquired consisted of $ 54.0 million customer relationships with an estimated amortization life of 14 years, $ 2.7 million trade name with an estimated amortization life of 7 years, and $ 360,000 in-place lease intangible asset to be amortized over the remaining lease term of 5 years. The fair value of the customer relationship was estimated using the Multiperiod Excess Earnings Method, or MPEEM, of the income approach. Under the MPEEM, an intangible asset’s fair value is equal to the present value of the incremental after-tax cash flows attributable only to the subject intangible asset after deducting contributory asset charges. The incremental after-tax cash flows attributable to the customer relationships are then discounted to their present value at a risk-adjusted rate of return. The fair value of the trade name was estimated using the relief from royalty, or RFR, method. The RFR method estimates the portion of the Company's earnings attributable to an intangible asset based on the royalty rate the Company would have paid for the use of the asset if it did not own it. The fair value of in-place lease intangible asset was estimated using the discounted cash flow under the income approach. The useful lives of the intangible assets for amortization purposes were determined by considering the period of expected cash flows used to measure the fair values of the intangible assets adjusted as appropriate for entity-specific factors including legal, regulatory, contractual, competitive, economic and other factors that may limit the useful life. The customer relationships and trade name are amortized on a straight-line basis over their estimated useful lives. Revenue and operating loss from the Inform Diagnostics acquisition since the acquisition date are $ 53.9 million and $ 11.2 million, respectively, which are included in the accompanying Condensed Consolidated Statements of Income. The transaction costs associated with the acquisition of Inform Diagnostics consisted primarily of legal, regulatory and financial advisory fees of approximately $ 166,000 and $ 6.6 million for the three and nine months ended September 30, 2022, respectively. These transaction costs were expensed as incurred as selling, general and administrative expense in the respective periods. Unaudited Pro Forma Financial Information The following unaudited pro forma financial information summarizes the combined results of operations of Fulgent and Inform Diagnostics as if the companies had been combined as of the beginning of 2021. The pro forma financial information has been adjusted for the following: Acquisition-related costs - Acquisition-related costs incurred by both Fulgent and Inform Diagnostics were excluded from the net income attributable to Fulgent, and total costs were $ 166,000 and $ 9.6 million for the three and nine months ended September 30, 2022, respectively. Other adjustments to the net income attributable to Fulgent were zero and $ 772,000 for three and nine months ended September 30, 2022, respectively, and $ 579,000 and $ 1.7 million for the three and nine months ended September 30, 2021, respectively. Other adjustments to revenue were zero and $ 962,000 million for the three and nine months ended September 30, 2022, respectively, and $ 1.3 million and $ 3.0 million were added back to revenue for the three and nine months ended September 30, 2021, respectively. Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (in thousands) Revenue $ 105,655 $ 261,809 $ 591,682 $ 851,660 Net income attributable to Fulgent $ 1,885 $ 121,053 $ 164,120 $ 403,631 Basic earnings per common share attributable to Fulgent $ 0.06 $ 4.08 $ 5.42 $ 13.81 Diluted earnings per common share attributable to Fulgent $ 0.06 $ 3.88 $ 5.28 $ 13.06

Stock Repurchase Program

Stock Repurchase Program	9 Months Ended
	Sep. 30, 2022
Stockholders' Equity Note [Abstract]
Stock Repurchase Program	Note 16. Stock Repurchase Program In March 2022, the Company's Board authorized a $ 250.0 million stock repurchase program. Under the stock repurchase program, the Company may repurchase shares from time to time in the open market or in privately negotiated transactions. The stock repurchase program has no expiration from the date of authorization. During the three months ended September 30, 2022, the Company repurchased 780,000 shares of its common stock at an aggregate cost of $ 34.7 million under the stock repurchase program. During the nine months ended September 30, 2022, the Company repurchased 995,000 shares of its common stock at an aggregate cost of $ 45.3 million under the stock repurchase program. As of September 30, 2022, a total of approximately $ 204.7 million remained available for future repurchases of its common stock under the stock repurchase program.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 17. Subsequent Events Fulgent Pharma Holdings Acquisition On November 7, 2022, the Company entered into and completed its acquisition of Fulgent Pharma Holdings, pursuant to an Agreement and Plan of Merger, or the Pharma Merger Agreement, by and among Fulgent Genetics, FG Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Fulgent Genetics, or Merger Sub, Fulgent Pharma Holdings, and solely for purposes of Section 2.4, Section 5.5, Article VI, Section 7.8 and Section 7.14 of the Pharma Merger Agreement, Mr. Hsieh and the Hsieh Trust. Under the terms of the Pharma Merger Agreement, Merger Sub merged with and into Fulgent Pharma Holdings, or the Pharma Merger, with Fulgent Pharma Holdings being the surviving corporation following the Pharma Merger. As consideration for the Pharma Merger, Fulgent Genetics paid an aggregate of approximately $ 100 million in exchange for all of the outstanding equity interests of Fulgent Pharma Holdings, comprised of approximately $ 43.4 million in cash, approximately $ 30.7 million in Fulgent Genetics’ common stock, or the Stock Consideration, subject to customary adjustments for closing cash, closing indebtedness, transaction expenses and other transaction matters. A portion of the Stock Consideration was held back for a duration of time after the closing of the transaction to satisfy certain indemnification obligations of the Pharma Stockholders as described in the Pharma Merger Agreement. In addition, restricted stock units to acquire shares of common stock of Fulgent Pharma Holdings held by Paul Kim, the Company’s Chief Financial Officer, Jian Xie, the Company’s President and Chief Operating Officer, Hanlin Gao, the Company’s Chief Scientific Officer and other employees of the Company and consultants of Fulgent Pharma LLC were assumed by the Company and became restricted stock units to acquire 77,585 , 129,309 , 51,723 , 117,398 , and 286,998 shares of common stock of the Company, respectively, which have an approximate value of $ 25.9 million. The restricted stock units are subject to vesting over the four-year period immediately following the date of their original grant, subject to the holder’s continuing service. The Pharma Merger Agreement contains representations, warranties and covenants by the parties customary for a transaction of this nature. Breaches of representations and warranties are subject to customary indemnification provisions. Stock Repurchase Program Subsequent to September 30, 2022 and as of October 31, 2022, the Company repurchased 244,000 shares of its common stock at an aggregate cost of $ 9.1 million under the stock repurchase program approved in March 2022. See Note 16, Stock Repurchase Program.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting periods. These estimates, judgments and assumptions are based on historical data and experience available at the date of the accompanying condensed consolidated financial statements, as well as various other factors management believes to be reasonable under the circumstances, including but not limited to the potential impacts arising from the recent global pandemic related to COVID-19. As the extent and duration of the impacts from COVID-19 remain unclear, the Company’s estimates and assumptions may evolve as conditions change. Actual results could differ significantly from these estimates. On an on-going basis, management evaluates its estimates, primarily those related to: (i) revenue recognition criteria; (ii) accounts receivable and allowances for credit losses; (iii) the useful lives of fixed assets and intangible assets; (iv) estimates of tax liabilities; and (v) valuation of intangible assets and goodwill.
Marketable Securities	Marketable Securities All marketable debt securities, which consist of corporate debt securities, municipal bonds, U.S. government and agency debt securities, U.S. treasury bills, and Yankee debt securities issued by foreign governments or entities and denominated in U.S. dollars have been classified as “available-for-sale,” and are carried at fair value. Net unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive income (loss) and reported as a separate component of stockholders’ equity until realized. Realized gains and losses on marketable debt securities are included in interest and other income, net, in the accompanying Condensed Consolidated Statements of Income. The cost of any marketable debt securities sold is based on the specific-identification method. The amortized cost of marketable debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on marketable debt securities is included in interest and other income, net. In accordance with the Company’s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities. The Company’s investments in marketable equity securities are measured at fair value with the related gains and losses, realized and unrealized, recognized in interest and other income, net, in the accompanying Condensed Consolidated Statements of Income. The cost of any marketable equity securities sold is based on the specific-identification method. For available-for-sale debt securities, in an unrealized loss, the Company determines whether a credit loss exists. The credit loss is estimated by considering available information relevant to the collectability of the security and information about past events, current conditions, and reasonable and supportable forecasts. The Company compares the present value of cash flows expected to be collected from the security with the amortized cost basis of the security. If the present value of cash flows to be collected is less than the amortized basis of the security, a credit loss exists, and any credit loss is recorded as a charge to interest and other income, net, not to exceed the amount of the unrealized loss. If the Company has an intent to sell, or if it is more likely than not that the Company will be required to sell a debt security in an unrealized loss position before recovery of its amortized cost basis, the Company will write down the security to its fair value and record the corresponding charge as a component of interest and other income, net.
Trade Accounts Receivable and Allowance for Credit Losses	Trade Accounts Receivable and Allowance for Credit Losses Trade accounts receivable are stated at the amount the Company expects to collect. The Company maintains an allowance for credit losses for expected uncollectible trade accounts receivable, which is recorded as an offset to trade accounts receivable, and changes in allowance for credit losses are classified as a general and administrative expense in the accompanying Condensed Consolidated Statements of Income. The Company assesses collectability by reviewing trade accounts receivable on a collective basis where similar risk characteristics exist and on an individual basis when it identifies specific customers that have deterioration in credit quality such that they may no longer share similar risk characteristics with the other receivables. In determining the amount of the allowance for credit losses, the Company uses a probability-of-default and loss given default model, which allows the ability to define a point of default and measure credit losses for receivables that have reached the point of default for purposes of calculating the allowance for credit losses. Loss given default represents the likelihood that a receivable that has reached the point of default will not be collected in full. The Company updates its probability-of-default and loss given default factors annually to incorporate the most recent historical data and adjusts the quantitative portion of the reserve through its qualitative reserve overlay. The Company looks at qualitative factors such as general economic conditions in determining expected credit losses. During the three and nine months ended September 30, 2022, the Company recorded $ 6.5 million and $ 25.3 million of provision for credit losses for trade accounts receivable, respectively. During the three and nine months ended September 30, 2021, the Company recorded $ 848,000 and $ 4.1 million of provision for credit losses for trade accounts receivable, respectively.
Redeemable Preferred Stock Investment	Redeemable Preferred Stock Investment The redeemable preferred stock investment of $ 11.2 million as of September 30, 2022 represents the fair value of redeemable preferred stock of a private company that the Company purchased in July 2021. The investment is classified as available-for-sale debt securities. The fair value of available-for-sale debt security is included in the Consolidated Statement of Balance Sheets. Unrealized losses of $ 748,000 and $ 10.7 million were excluded from earnings and reported in other comprehensive loss for the three and nine months ended September 30, 2022. There was no unrealized gain or loss in the three and nine months ended September 30, 2021. Since the Company intends on holding the preferred stock, and the preferred stock is not redeemable until July 2027 , the investment is recorded as a long-term investment.
Foreign Currency Translation and Foreign Currency Transactions	Foreign Currency Translation and Foreign Currency Transactions The Company translates the assets and liabilities of its non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recognized in foreign currency translation included in accumulated other comprehensive income (loss) in the accompanying Condensed Consolidated Statements of Stockholders’ Equity. Loss from these translations were $ 1.9 million and $ 3.7 million in the three and nine months ended September 30, 2022, respectively. Loss from these translations were not significant in the three and nine months ended September 30, 2021. The Company and its subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period, whereas reagents and supplies, property and nonmonetary assets and liabilities are measured at historical rates. Losses from these remeasurements were not significant in the three and nine months ended September 30, 2022 and 2021.
Comprehensive Income (Loss)	Comprehensive Income (Loss) Comprehensive income (loss) is comprised of net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) consists of net unrealized gain or loss on available-for-sale d ebt securities, net of tax, and foreign currency translation adjustments from the Company's subsidiaries not using the U.S. dollar as their functional currency. Reclassifications from other comprehensive income (loss) to net earnings were not significant in the three and nine months ended September 30, 2022 and 2021. The tax effects related to net unrealized loss on available-for-sale debt securities were $ 3.6 million and $ 9.4 million in the three and nine months ended September 30, 2022, respectively. The tax effects were no t significant in the three and nine months ended September 30, 2021 .
Leases	Leases The Company determines if an arrangement is a lease at inception by evaluating whether the arrangement conveys the right to use an identified asset and whether the Company obtains substantially all of the economic benefits from and has the ability to direct the use of the asset. Operating and finance lease right-of-use assets, or ROU assets, short-term lease liabilities, and long-term lease liabilities are included in other long-term assets, accrued liabilities, and other long-term liabilities, respectively, in the accompanying Condensed Consolidated Balance Sheets. Lease ROU assets represent the Company’s right to use an underlying asset for the lease term. Lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term, including options to extend the lease when it is reasonably certain that the Company will exercise that option. The Company uses its incremental borrowing rate based on the information available at the commencement date, including inquiries with its bank, in determining the present value of lease payments since its leases do not provide an implicit rate. Lease ROU assets consist of initial measurement of lease liabilities, any lease payments made to lessor on or before the lease commencement date, minus any lease incentive received, and any initial direct costs incurred by the Company. Operating lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance lease, ROU assets are amortized on a straight-line basis from the commencement date to the earlier of the end of useful life of the ROU assets or the end of the lease term. Amortization of ROU assets and interest on the lease liability for finance leases are included as charges to the accompanying Condensed Consolidated Statements of Income. Lease ROU assets and liabilities arising from business combinations are recognized and measured at the acquisition dates as if an acquired lease were a new lease at the date of acquisition using the Company’s incremental borrowing rate unless the discount rate is implicit in the lease. The Company elects to not to recognize assets or liabilities as of the acquisition dates for leases that, on the acquisition dates, have a remaining lease term of 12 months or less. The Company also retains the acquirees’ classification of the leases if there are no modifications as part of the business combinations. The Company leases and subleases out space in buildings it owns or leases to third-party tenants or subtenants under noncancelable operating leases. The Company recognizes lease payments as income over the lease terms on a straight-line basis and recognizes variable lease payments as income in the period in which the changes in facts and circumstances on which the variable lease payments are based occur. The net rental income is included in the interest and other income, net, in the accompanying Condensed Consolidated Statements of Income.
Concentration of Customers	Concentration of Customers In certain periods, a small number of customers have accounted for a significant portion of the Company’s revenue. After aggregating customers that are under common control or affiliation, one customer contributed 13 % and 21 % of the Company's revenue for the three and nine months ended September 30, 2022, respectively. Two customers contributed 31 % and 11 %, respectively, of the Company’s revenue for the three months ended September 30, 2021, and one customer contributed 26 % of the Company’s revenue for the nine months ended September 30, 2021. No single customer comprised 10 % or more of total accounts receivable as of September 30, 2022 and December 31, 2021.
Revenue from Contracts with Customers	Disaggregation of Revenue The Company classifies its customers into three payor types: (i) Insurance, including claim reimbursement from the U.S. Health Resources and Services Administration, or H RSA, for uninsured individuals, (ii) Institutional customers, including hospitals, medical institutions, other laboratories, governmental bodies, municipalities and large corporations, or (iii) Patients who pay directly, as the Company believes this best depicts how the nature, amount, timing, and uncertainty of its revenue and cash flows are affected by economic factors. The following table summarizes revenue from contracts with customers by payor type for the three and nine months ended September 30, 2022 and 2021. Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (in thousands) Testing Services by payor Insurance $ 63,030 $ 143,276 $ 337,497 $ 400,354 Institutional customers 42,280 84,401 212,980 339,572 Patients 345 191 787 987 Total Revenue $ 105,655 $ 227,868 $ 551,264 $ 740,913 The insurance revenue category above includes zero and $ 81.9 million for the three months ended September 30, 2022 and 2021, respectively, and $ 92.7 million and $ 231.5 million for the nine months ended September 30, 2022 and 2021, respectively, for services related to claims covered by the HRSA COVID-19 Uninsured Program. The HRSA program stopped accepting claims at 11:59 p.m. on March 22, 2022. There was no material variable consideration recognized in the current period that relates to performance obligations that were completed in the prior period. Collection of the Company’s net revenues from insurers is normally a function of providing complete and correct billing information within the various filing deadlines. Provided the Company has billed insurers accurately with complete information prior to the established filing deadline, there has historically been little to no credit risk. If there has been a delay in billing, the Company determines if the amounts in question will likely go past the filing deadline, and if so, the Company will reserve accordingly for the billing. Contract Balances Receivables from contracts with customers - Receivables from contracts with customers are included within trade accounts receivable on the Condensed Consolidated Balance Sheets. Net receivable from Insurance and Institutional customers represented 78 % and 22 %, respectively, as of September 30, 2022. Net receivable from Insurance and Institutional customers represented 47 % and 53 %, respectively, as of December 31, 2021. Contracts assets and liabilities - Contract assets from contracts with customers associated with contract execution and certain costs to fulfill a contract are included in other current assets in the accompanying Condensed Consolidated Balance Sheets. Contract liabilities are recorded when the Company receives payment prior to completing its obligation to transfer goods or services to a customer. Contract liabilities are included in the Condensed Consolidated Balance Sheets. Revenues of $ 8.5 million and $ 5.7 million were recognized for the three months ended September 30, 2022 and 2021, respectively, and $ 14.4 million and $ 26.4 million were recognized for the nine months ended September 30, 2022 and 2021, respectively, related to contract liabilities at the beginning of the respective periods.
Reagents and Supplies	Reagents and Supplies The Company maintains reagents and other consumables primarily used in sample collections and testing which are valued at the lower of cost or net realizable value. Cost is determined using actual costs on a first-in, first-out basis. The reagents and supplies were included in other current assets in the accompanying Condensed Consolidated Balance Sheets.
Customer Deposit	Customer Deposit Customer deposit in the accompanying Condensed Consolidated Balance Sheets consists of payments received from customers in excess of their outstanding trade accounts receivable balances or amounts customers believe were potentially paid in error. These deposits will be offset against future testing receivables or refunded to the customers. The largest deposit as of September 30, 2022 was recorded in the amount of $ 16.0 million.
Business Combination	Business Combination The Company uses the acquisition method of accounting and allocates the fair value of purchase consideration to the assets acquired and liabilities assumed from an acquiree based on their respective fair values as of the acquisition date. The excess of the fair value of purchase consideration over the fair value of these assets acquired and liabilities assumed is recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions, especially with respect to intangible assets. Critical estimates in valuing intangible assets include, but are not limited to, expected future cash flows, which includes consideration of future growth and margins, future changes in technology, expected cost and time to develop in-process research and development, brand awareness and discount rates. Fair value estimates are based on the assumptions that management believes a market participant would use in pricing the asset or liability.
Goodwill	Goodwill Goodwill is not amortized but is subject to impairment tests on an annual basis, or more frequently if indicators of potential impairment exist, and goodwill is written down when it is determined to be impaired. The Company typically performs an annual impairment review in the fourth quarter of each fiscal year unless one had been performed previously within the past 12 months and compares the fair value of the reporting unit in which the goodwill resides to its carrying value.
Restructuring Costs	Restructuring Costs Restructuring costs represent one-time employee termination benefits provided to employees associated with a newly acquired entity that were involuntarily terminated. A plan of termination was approved and authorized by management in the second quarter of 2022. The plan identified specific employees to be terminated and established terms of benefits those employees would receive upon termination. Total restructuring costs incurred in the three and nine months ended September 30, 2022 were $ 105,000 and $ 3.0 million , respectively, and payable balance as of September 30, 2022 was $ 2.0 million, which is included in accrued liabilities in the accompanying Condensed Consolidated Balance Sheets. No additional costs are expected to be incurred under the plan of termination, and the payable balance is expected to be paid off by August 2023 . There were no such costs in the prior fiscal year.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company evaluates all Accounting Standards Updates, or ASUs, issued by the Financial Accounting Standards Board, or FASB, for consideration of their applicability. ASUs not included in the Company’s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company’s condensed consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Standards Update 2014-09
Summary of Revenue from Contracts with Customers by Payor Type	The following table summarizes revenue from contracts with customers by payor type for the three and nine months ended September 30, 2022 and 2021. Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (in thousands) Testing Services by payor Insurance $ 63,030 $ 143,276 $ 337,497 $ 400,354 Institutional customers 42,280 84,401 212,980 339,572 Patients 345 191 787 987 Total Revenue $ 105,655 $ 227,868 $ 551,264 $ 740,913

Equity and Debt Securities (Tab

Equity and Debt Securities (Tables)	9 Months Ended
	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Summary of Equity and Debt Securities	The Company’s equity and debt securities consisted of the following: September 30, 2022 Amortized Unrealized Unrealized Aggregate (in thousands) Equity securities: Long-term Preferred stock of privately held company $ 15,000 $ — $ — 15,000 Total equity securities 15,000 — — 15,000 Available-for-sale debt securities Short-term U.S. government debt securities 181,333 — ( 2,824 ) 178,509 Corporate debt securities 124,181 — ( 2,120 ) 122,061 Money market accounts 87,382 — — 87,382 U.S. treasury bills 72,522 6 ( 285 ) 72,243 U.S. agency debt securities 32,505 — ( 483 ) 32,022 Municipal bonds 8,058 — ( 123 ) 7,935 Yankee debt securities 7,582 — ( 147 ) 7,435 Less: Cash equivalents ( 105,292 ) ( 5 ) — ( 105,297 ) Total debt securities due within 1 year 408,271 1 ( 5,982 ) 402,290 After 1 year through 5 years U.S. government debt securities 181,464 — ( 8,261 ) 173,203 Corporate debt securities 114,848 — ( 6,584 ) 108,264 U.S. agency debt securities 52,230 — ( 3,467 ) 48,763 Municipal bonds 12,929 — ( 382 ) 12,547 Yankee debt securities 753 — ( 100 ) 653 Redeemable preferred stock investment 20,000 — ( 8,767 ) 11,233 Total debt securities due after 1 year through 5 years 382,224 — ( 27,561 ) 354,663 After 5 years through 10 years Municipal bonds 3,654 — ( 138 ) 3,516 Total debt securities due after 5 years through 10 years 3,654 — ( 138 ) 3,516 Total available-for-sale debt securities 794,149 1 ( 33,681 ) 760,469 Total equity and debt securities $ 809,149 $ 1 $ ( 33,681 ) $ 775,469 December 31, 2021 Amortized Unrealized Unrealized Aggregate (in thousands) Equity securities: Short-term Bond funds $ 99,314 $ — $ ( 515 ) $ 98,799 Exchange traded funds 35,174 — ( 174 ) 35,000 Total equity securities 134,488 — ( 689 ) 133,799 Available-for-sale debt securities Short-term Corporate debt securities 92,116 24 ( 148 ) 91,992 Money market accounts 77,067 — — 77,067 U.S. government debt securities 51,318 — ( 81 ) 51,237 Municipal bonds 4,980 — ( 12 ) 4,968 Yankee debt securities 3,615 — ( 6 ) 3,609 Less: Cash equivalents ( 77,067 ) — — ( 77,067 ) Total debt securities due within 1 year 152,029 24 ( 247 ) 151,806 After 1 year through 5 years Corporate debt securities 242,421 29 ( 1,913 ) 240,537 U.S. Government debt securities 147,699 7 ( 786 ) 146,920 U.S. agency debt securities 70,069 — ( 535 ) 69,534 Municipal bonds 11,920 13 ( 11 ) 11,922 Yankee debt securities 8,633 — ( 89 ) 8,544 Total debt securities due after 1 year through 5 years 480,742 49 ( 3,334 ) 477,457 After 5 years through 10 years Municipal bonds 7,633 — ( 43 ) 7,590 Redeemable preferred stock investment 20,000 1,965 — 21,965 Total debt securities due after 5 years through 10 years 27,633 1,965 ( 43 ) 29,555 Total available-for-sale debt securities 660,404 2,038 ( 3,624 ) 658,818 Total equity and debt securities $ 794,892 $ 2,038 $ ( 4,313 ) $ 792,617

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Information about Financial Assets Measured at Fair Value on Recurring Basis Based on Three-Tier Fair Value Hierarchy	The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the above three-tier fair value hierarchy: September 30, 2022 Total Level 1 Level 2 Level 3 (in thousands) Equity securities, debt securities and cash equivalents: U.S. government debt securities $ 351,712 $ — $ 351,712 $ — Corporate debt securities 230,325 — 230,325 — Money market accounts 87,382 87,382 — — U.S. agency debt securities 80,785 — 80,785 — U.S. treasury bills 72,243 72,243 — — Municipal bonds 23,998 — 23,998 — Preferred stock of privately held company 15,000 — — 15,000 Redeemable preferred stock investment 11,233 — — 11,233 Yankee debt securities 8,088 — 8,088 — Total equity securities, debt securities and cash equivalents $ 880,766 $ 159,625 $ 694,908 $ 26,233 December 31, 2021 Total Level 1 Level 2 Level 3 (in thousands) Equity securities, debt securities and cash equivalents: Corporate debt securities $ 332,529 $ — $ 332,529 $ — U.S. government debt securities 198,157 — 198,157 — Bond funds 98,799 98,799 — — U.S. agency debt securities 69,534 — 69,534 — Exchange traded funds 35,000 35,000 — — Municipal bonds 24,480 — 24,480 — Yankee debt securities 12,153 — 12,153 — Redeemable preferred stock investment 21,965 — — 21,965 Money market accounts 77,067 77,067 — — Total equity securities, debt securities and cash equivalents $ 869,684 $ 210,866 $ 636,853 $ 21,965

Fixed Assets (Tables)

Fixed Assets (Tables)	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Major Classes of Fixed Assets	Major classes of fixed assets consisted of the following: September 30, December 31, Useful Lives 2022 2021 (in thousands) Medical lab equipment 1 to 12 Years $ 48,570 $ 35,930 Leasehold improvements Shorter of lease term or estimated useful life 11,175 4,003 Computer hardware 1 to 5 Years 6,906 5,661 Computer software 1 to 5 Years 6,793 1,408 Building 39 Years 6,731 6,731 Aircraft 7 Years 6,503 6,503 Building improvements 6 months to 39 Years 5,749 3,936 Furniture and fixtures 1 to 5 Years 4,160 2,255 Automobile 2 to 7 Years 811 825 Land improvements 5 to 15 Years 616 403 General equipment 3 to 5 Years 44 44 Land 7,500 7,500 Assets not yet placed in service 12,215 6,718 Total 117,773 81,917 Less: Accumulated depreciation ( 35,966 ) ( 19,630 ) Fixed assets, net $ 81,807 $ 62,287

Other Balance Sheet Accounts (T

Other Balance Sheet Accounts (Tables)	9 Months Ended
	Sep. 30, 2022
Balance Sheet Related Disclosures [Abstract]
Schedule of Other Current Assets	Other current assets consisted of the following: September 30, December 31, 2022 2021 (in thousands) Prepaid expenses $ 8,399 $ 4,244 Reagents and supplies 7,509 12,206 Marketable securities interest receivable 2,733 2,743 Prepaid income taxes 2,055 1,716 Other receivable 699 1,403 Contract assets — 237 Total $ 21,395 $ 22,549
Schedule of Other Current Liabilities	Other current liabilities consisted of the following: September 30, December 31, 2022 2021 (in thousands) Payable to a broker $ 12,905 $ — Other 716 680 Total $ 13,621 $ 680

Reporting Segment and Geograp_2

Reporting Segment and Geographic Information (Tables)	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Summary of Revenue by Geographic Region	Revenue by region during the three and nine months ended September 30, 2022 and 2021 were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (in thousands) Revenue: United States $ 101,515 $ 223,685 $ 540,801 $ 731,084 Foreign 4,140 4,183 10,463 9,829 Total $ 105,655 $ 227,868 $ 551,264 $ 740,913

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Schedule of Operating and Finance Lease Right-of-Use Asset, Short-term Lease Liabilities, and Long-term Lease Liabilities	The operating and finance lease right-of-use asset, short-term lease liabilities, and long-term lease liabilities as of September 30, 2022 and December 31, 2021 were as follows: September 30, December 31, 2022 2021 (in thousands) Operating lease ROU asset, net $ 16,363 $ 7,141 Operating lease liabilities, short term $ 6,184 $ 1,842 Operating lease liabilities, long term $ 10,282 $ 5,344 Finance lease ROU asset, net $ 3,010 $ 1,735 Finance lease liabilities, short term $ 927 $ 332 Finance lease liabilities, long term $ 2,050 $ 1,398
Schedule of Operating and Finance Lease Expense	The following was operating and finance lease expense: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (in thousands) Operating lease cost $ 1,770 $ 429 $ 3,674 $ 730 Finance lease cost: Amortization of ROU assets 225 3 490 3 Interest on lease liabilities 31 — 66 — Short-term lease cost 112 53 1,042 245 Total lease cost $ 2,138 $ 485 $ 5,272 $ 978
Schedule of Supplemental Information Related to Operating Leases and Finance Leases	Supplemental information related to operating leases and finance lease was the following: September 30, 2022 Weighted average remaining lease term - operating leases 3.39 years Weighted average discount rate - operating leases 3.82 % Weighted average remaining lease term -finance lease 3.33 years Weighted average discount rate - finance lease 3.98 %
Schedule of Maturity Analysis of Operating and Finance Lease Liabilities using Undiscounted Cash Flows on an Annual Basis	The following is a maturity analysis of operating and finance lease liabilities using undiscounted cash flows on an annual basis with renewal periods included: Operating Leases Finance Lease (in thousands) Year Ending December 31, 2022 (remaining 3 months) $ 1,717 $ 207 2023 6,579 1,033 2024 4,063 1,026 2025 2,112 544 2026 1,521 366 2027 1,360 — Thereafter 217 — Total lease payments 17,569 3,176 Less imputed interest ( 1,103 ) ( 199 ) Total $ 16,466 $ 2,977
Schedule of Lease Income	Total lease income was as follows: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (in thousands) Lease income $ 48 $ 78 $ 229 $ 315 Variable lease income — 1 12 6 Total lease income $ 48 $ 79 $ 241 $ 321
Schedule of Future Fixed Lease Payments from Tenants for All Noncancelable Operating Leases	Future fixed lease payments from tenants for all noncancelable operating leases as of September 30, 2022 are as follows: Lease Payments from Tenants (in thousands) Year Ending December 31, 2022 (remaining 3 months) $ 40 2023 93 2024 3 2025 — Total $ 136

Equity-Based Compensation (Tabl

Equity-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Equity-Based Compensation	The Company has included equity-based compensation expense as part of cost of revenue and operating expenses in the accompanying Condensed Consolidated Statements of Income as follows: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (in thousands) Cost of revenue $ 2,475 $ 962 $ 6,183 $ 2,328 Research and development 2,687 1,757 7,110 4,461 Selling and marketing 1,243 693 3,148 1,739 General and administrative 2,567 962 6,177 2,334 Total $ 8,972 $ 4,374 $ 22,618 $ 10,862

Income per Share (Tables)

Income per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Reconciliation of the Basic and Diluted Income Per Share Computations	The following table presents the calculation of basic and diluted income per share for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (in thousands, except per share data) Net income attributable to Fulgent $ 1,719 $ 122,522 $ 167,235 $ 403,025 Weighted-average common shares—outstanding, basic 30,174 29,673 30,256 29,221 Weighted-average common shares—outstanding, diluted 30,867 31,170 31,107 30,906 Net income per common share, basic $ 0.06 $ 4.13 $ 5.53 $ 13.79 Net income per common share, diluted $ 0.06 $ 3.93 $ 5.38 $ 13.04
Anti-dilutive Securities Excluded from Calculation of Diluted Income Per Share	The following securities have been excluded from the calculation of diluted income per share because their effect would have been anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (in thousands) Options 7 5 10 5 Restricted Stock Units 1,238 241 697 129

Goodwill and Acquisition-Rela_2

Goodwill and Acquisition-Related Intangibles (Tables)	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Summaries of Goodwill and Acquisitions-Related Intangibles Balances	Summaries of goodwill and intangibles balances assets as of September 30, 2022 and December 31, 2021 were as follows: September 30, December 31, Weighted-Average Amortization Period 2022 2021 (in thousands) Goodwill $ 120,313 $ 50,897 Royalty-free technology 10 Years $ 5,201 $ 5,803 Less: accumulated amortization ( 737 ) ( 387 ) Royalty-free technology, net 4,464 5,416 Customer relationships 13 Years 82,715 28,845 Less: accumulated amortization ( 4,608 ) ( 1,125 ) Customer relationships, net 78,107 27,720 Trade name 8 Years 3,790 1,090 Less: accumulated amortization ( 288 ) ( 45 ) Trade name, net 3,502 1,045 In-place lease intangible assets 5 Years 360 — Less: accumulated amortization ( 29 ) — In-place lease intangible assets, net 331 — Laboratory information system platform 5 Years 1,860 1,860 Less: accumulated amortization ( 434 ) ( 155 ) Laboratory information system platform, net 1,426 1,705 Purchased patent 10 Years 28 31 Less: accumulated amortization ( 5 ) ( 3 ) Purchased patent, net 23 28 Total intangible assets, net $ 87,853 $ 35,914
Summary of Carrying Amount of Goodwill	Changes in the carrying amount of goodwill for the nine months ended September 30, 2022 are as follows: Amounts (in thousands) Balance as of January 1, 2022 Goodwill $ 50,897 Accumulated impairment losses — 50,897 Goodwill acquired during year 71,844 Net exchange differences ( 2,428 ) Balance as of September 30, 2022 Goodwill 120,313 Accumulated impairment losses — $ 120,313
Summary of Annual Amortization Expense For Acquisition-Related Intangibles	Based on the carrying value of intangible assets recorded as of September 30, 2022, and assuming no subsequent impairment of the underlying assets, the annual amortization expense for intangible assets is expected to be as follows: Amounts (in thousands) Year Ending December 31, 2022 (remaining 3 months) $ 1,960 2023 7,841 2024 7,841 2025 7,841 2026 7,536 2027 7,209 Thereafter 47,625 Total $ 87,853

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
	Sep. 30, 2022
Business Combinations [Abstract]
Summary of Consideration Paid and Amount of Assets Acquired and Liabilities Assumed	The following tables summarizes the consideration paid and the updated amounts of the assets acquired and liabilities assumed recognized at the acquisition date: Amounts (in thousands) Considerations Cash, net of cash received $ 137,755 Recognized amounts of identifiable assets acquired and liabilities assumed Net working capital $ ( 15,024 ) Fixed assets 20,242 ROU assets - operating 12,653 ROU assets - finance 1,183 Deferred tax assets 3,410 Other long-term assets 4,711 Identifiable intangible assets 57,060 Operating lease liabilities ( 12,653 ) Finance lease liabilities ( 1,183 ) Income tax payable ( 40 ) Other long-term liabilities ( 4,449 ) Recognized amounts of identifiable assets acquired and liabilities assumed, net 65,910 Goodwill 71,845 Total $ 137,755
Summary of Unaudited Pro Forma Financial Information	The following unaudited pro forma financial information summarizes the combined results of operations of Fulgent and Inform Diagnostics as if the companies had been combined as of the beginning of 2021. The pro forma financial information has been adjusted for the following: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (in thousands) Revenue $ 105,655 $ 261,809 $ 591,682 $ 851,660 Net income attributable to Fulgent $ 1,885 $ 121,053 $ 164,120 $ 403,631 Basic earnings per common share attributable to Fulgent $ 0.06 $ 4.08 $ 5.42 $ 13.81 Diluted earnings per common share attributable to Fulgent $ 0.06 $ 3.88 $ 5.28 $ 13.06

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022 USD ($) Customer	Sep. 30, 2021 USD ($) Customer	Sep. 30, 2022 USD ($) Customer	Sep. 30, 2021 USD ($) Customer	Dec. 31, 2021 USD ($) Customer
Summary Of Significant Accounting Policies [Line Items]
Contract with customer liability, revenue recognized	$ 8,500,000	$ 5,700,000	$ 14,400,000	$ 26,400,000
Provision for credit losses for trade accounts receivable	6,500,000	848,000	25,256,000	4,107,000
Redeemable preferred stock investment	11,233,000		11,233,000		$ 21,965,000
Unrealized gains or losses	748,000	0	$ 10,700,000	0
Preferred stock, redemption date			Jul. 31, 2027
Foreign currency translation loss	(1,925,000)	(114,000)	$ (3,680,000)	(78,000)
Tax effects related to unrealized holding loss on available-for-sale debt securities	3,600,000	0	9,400,000	0
Revenue	105,655,000	227,868,000	551,264,000	740,913,000
Additional costs expected to be incurred	0		$ 0
Payable balance, expected paid off date			2023-08
Restructuring costs	105,000		$ 3,001,000		$ 0
Largest customer deposit	16,000,000		16,000,000
Accrued Liabilities
Summary Of Significant Accounting Policies [Line Items]
Restructuring costs, payable balance	2,000,000		2,000,000
Clinical Insurance Contracts | HSRA COVID-19 Uninsured Program
Summary Of Significant Accounting Policies [Line Items]
Revenue	$ 0	$ 81,900,000	$ 92,700,000	$ 231,500,000
Insurance Customer
Summary Of Significant Accounting Policies [Line Items]
Percentage of net accounts receivable from contract	78%		78%		47%
Institutional Customer
Summary Of Significant Accounting Policies [Line Items]
Percentage of net accounts receivable from contract	22%		22%		53%
Customer Concentration Risk | Revenue
Summary Of Significant Accounting Policies [Line Items]
Number of customers | Customer	1	2	1	1
Customer Concentration Risk | Revenue | Customer One
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	13%	31%	21%	26%
Customer Concentration Risk | Revenue | Customer Two
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage		11%
Minimum | Customer Concentration Risk | Accounts Receivable
Summary Of Significant Accounting Policies [Line Items]
Number of customers | Customer			0		0
Concentration risk, percentage			10%		10%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Revenue from Contracts with Customers by Payor Type (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers by payor type	$ 105,655	$ 227,868	$ 551,264	$ 740,913
Accounting Standards Update 2014-09
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers by payor type	105,655	227,868	551,264	740,913
Accounting Standards Update 2014-09 | Clinical Insurance Contracts
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers by payor type	63,030	143,276	337,497	400,354
Accounting Standards Update 2014-09 | Clinical Institutional Customers Contracts
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers by payor type	42,280	84,401	212,980	339,572
Accounting Standards Update 2014-09 | Clinical Patients Contracts
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers by payor type	$ 345	$ 191	$ 787	$ 987

Equity and Debt Securities - Su

Equity and Debt Securities - Summary of Equity -Based Compensation (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Cash and cash equivalents	$ 168,770	$ 164,894
Less: Cash equivalents, Carrying Value	(105,292)	(77,067)
Cash equivalents, Unrealized Gains	(5)
Less: Cash equivalents, Fair Value	(105,297)	(77,067)
Equity and debt securities, Amortized Cost Basis	809,149	794,892
Equity and debt securities, Unrealized Gains	1	2,038
Equity and debt securities, Unrealized Losses	(33,681)	(4,313)
Equity and debt securities, Aggregate Fair Value	775,469	792,617
Debt Securities
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Debt securities, Amortized Cost Basis	794,149	660,404
Debt securities, Unrealized Gains	1	2,038
Debt securities, Unrealized Losses	(33,681)	(3,624)
Debt securities, Aggregate Fair Value	760,469	658,818
Short-Term Marketable Securities
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Debt securities, Amortized Cost Basis	408,271	152,029
Debt securities, Unrealized Gains	1	24
Debt securities, Unrealized Losses	(5,982)	(247)
Debt securities, Aggregate Fair Value	402,290	151,806
Short-Term Marketable Securities | Corporate Debt Securities
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Debt securities, Amortized Cost Basis	124,181	92,116
Debt securities, Unrealized Gains		24
Debt securities, Unrealized Losses	(2,120)	(148)
Debt securities, Aggregate Fair Value	122,061	91,992
Short-Term Marketable Securities | Money Market Accounts
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Cash and cash equivalents	87,382
Cash and cash equivalents fair value disclosure	87,382
Short-Term Marketable Securities | U.S. Treasury Bills
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Debt securities, Amortized Cost Basis	72,522
Debt securities, Unrealized Gains	6
Debt securities, Unrealized Losses	(285)
Debt securities, Aggregate Fair Value	72,243
Short-Term Marketable Securities | U.S. Government Debt Securities
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Debt securities, Amortized Cost Basis	181,333	51,318
Debt securities, Unrealized Losses	(2,824)	(81)
Debt securities, Aggregate Fair Value	178,509	51,237
Short-Term Marketable Securities | U.S. agency Debt Securities
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Debt securities, Amortized Cost Basis	32,505
Debt securities, Unrealized Losses	(483)
Debt securities, Aggregate Fair Value	32,022
Short-Term Marketable Securities | Municipal Bonds
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Debt securities, Amortized Cost Basis	8,058	4,980
Debt securities, Unrealized Losses	(123)	(12)
Debt securities, Aggregate Fair Value	7,935	4,968
Short-Term Marketable Securities | Yankee Debt Securities
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Debt securities, Amortized Cost Basis	7,582	3,615
Debt securities, Unrealized Losses	(147)	(6)
Debt securities, Aggregate Fair Value	7,435	3,609
Short-Term Equity Securities
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Marketable and non-marketable securities, Amortized Cost Basis		134,488
Marketable and non-marketable securities, Unrealized Losses		(689)
Marketable and non-marketable securities, Aggregate Fair Value		133,799
Short-Term Equity Securities | Bond Funds
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Marketable and non-marketable securities, Amortized Cost Basis		99,314
Marketable and non-marketable securities, Unrealized Losses		(515)
Marketable and non-marketable securities, Aggregate Fair Value		98,799
Short-Term Equity Securities | Exchange Traded Funds
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Marketable and non-marketable securities, Amortized Cost Basis		35,174
Marketable and non-marketable securities, Unrealized Losses		(174)
Marketable and non-marketable securities, Aggregate Fair Value		35,000
Short-Term Equity Securities | Money Market Accounts
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Cash and cash equivalents		77,067
Cash and cash equivalents fair value disclosure		77,067
Long Term Equity Securities
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Marketable and non-marketable securities, Amortized Cost Basis	15,000
Marketable and non-marketable securities, Aggregate Fair Value	15,000
Long Term Equity Securities | Preferred Stock Of Privately Held Company
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Marketable and non-marketable securities, Amortized Cost Basis	15,000
Marketable and non-marketable securities, Aggregate Fair Value	15,000
Equity Securities due After 1 Year through 5 Years
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Debt securities, Amortized Cost Basis	382,224	480,742
Debt securities, Unrealized Gains		49
Debt securities, Unrealized Losses	(27,561)	(3,334)
Debt securities, Aggregate Fair Value	354,663	477,457
Equity Securities due After 1 Year through 5 Years | Corporate Debt Securities
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Debt securities, Amortized Cost Basis	114,848	242,421
Debt securities, Unrealized Gains		29
Debt securities, Unrealized Losses	(6,584)	(1,913)
Debt securities, Aggregate Fair Value	108,264	240,537
Equity Securities due After 1 Year through 5 Years | U.S. Government Debt Securities
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Debt securities, Amortized Cost Basis	181,464	147,699
Debt securities, Unrealized Gains		7
Debt securities, Unrealized Losses	(8,261)	(786)
Debt securities, Aggregate Fair Value	173,203	146,920
Equity Securities due After 1 Year through 5 Years | U.S. agency Debt Securities
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Debt securities, Amortized Cost Basis	52,230	70,069
Debt securities, Unrealized Losses	(3,467)	(535)
Debt securities, Aggregate Fair Value	48,763	69,534
Equity Securities due After 1 Year through 5 Years | Municipal Bonds
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Debt securities, Amortized Cost Basis	12,929	11,920
Debt securities, Unrealized Gains		13
Debt securities, Unrealized Losses	(382)	(11)
Debt securities, Aggregate Fair Value	12,547	11,922
Equity Securities due After 1 Year through 5 Years | Yankee Debt Securities
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Debt securities, Amortized Cost Basis	753	8,633
Debt securities, Unrealized Losses	(100)	(89)
Debt securities, Aggregate Fair Value	653	8,544
Equity Securities due After 1 Year through 5 Years | Redeemable Preferred Stock Investment
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Debt securities, Amortized Cost Basis	20,000
Debt securities, Unrealized Losses	(8,767)
Debt securities, Aggregate Fair Value	11,233
Equity Securities due After 5 Year through 10 Years
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Debt securities, Amortized Cost Basis	3,654	27,633
Debt securities, Unrealized Gains		1,965
Debt securities, Unrealized Losses	(138)	(43)
Debt securities, Aggregate Fair Value	3,516	29,555
Equity Securities due After 5 Year through 10 Years | Municipal Bonds
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Debt securities, Amortized Cost Basis	3,654	7,633
Debt securities, Unrealized Losses	(138)	(43)
Debt securities, Aggregate Fair Value	$ 3,516	7,590
Equity Securities due After 5 Year through 10 Years | Redeemable Preferred Stock Investment
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Debt securities, Amortized Cost Basis		20,000
Debt securities, Unrealized Gains		1,965
Debt securities, Aggregate Fair Value		$ 21,965

Equity and Debt Securities - Ad

Equity and Debt Securities - Additional Information (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Schedule Of Available For Sale And Trading Securities [Line Items]
Gross unrealized loss	$ 33,700	$ 4,300
Outstanding borrowing amount	14,999	$ 15,137
Margin Account Borrowing
Schedule Of Available For Sale And Trading Securities [Line Items]
Total debt securities	$ 489,700

Fair Value Measurements - Infor

Fair Value Measurements - Information about Financial Assets Measured at Fair Value on Recurring Basis Based on Three-Tier Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Level 3 | Redeemable Preferred Stock Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total debt securities	$ 11,200
Fair Value Measurements Recurring
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total equity securities, debt securities and cash equivalents	880,766	$ 869,684
Fair Value Measurements Recurring | U.S. Government Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total debt securities	351,712	198,157
Fair Value Measurements Recurring | Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total debt securities	230,325	332,529
Fair Value Measurements Recurring | Money Market Accounts
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents fair value disclosure	87,382	77,067
Fair Value Measurements Recurring | Bond Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total equity trading securities		98,799
Fair Value Measurements Recurring | U.S. Agency Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total debt securities	80,785	69,534
Fair Value Measurements Recurring | U.S. Treasury Bills
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total debt securities	72,243
Fair Value Measurements Recurring | Exchange Traded Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total equity trading securities		35,000
Fair Value Measurements Recurring | Municipal Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total debt securities	23,998	24,480
Fair Value Measurements Recurring | Preferred Stock Of Privately Held Company
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total debt securities	15,000
Fair Value Measurements Recurring | Redeemable Preferred Stock Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total debt securities	11,233	21,965
Fair Value Measurements Recurring | Yankee Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total debt securities	8,088	12,153
Fair Value Measurements Recurring | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total equity securities, debt securities and cash equivalents	159,625	210,866
Fair Value Measurements Recurring | Level 1 | Money Market Accounts
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents fair value disclosure	87,382	77,067
Fair Value Measurements Recurring | Level 1 | Bond Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total equity trading securities		98,799
Fair Value Measurements Recurring | Level 1 | U.S. Treasury Bills
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total debt securities	72,243
Fair Value Measurements Recurring | Level 1 | Exchange Traded Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total equity trading securities		35,000
Fair Value Measurements Recurring | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total equity securities, debt securities and cash equivalents	694,908	636,853
Fair Value Measurements Recurring | Level 2 | U.S. Government Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total debt securities	351,712	198,157
Fair Value Measurements Recurring | Level 2 | Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total debt securities	230,325	332,529
Fair Value Measurements Recurring | Level 2 | U.S. Agency Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total debt securities	80,785	69,534
Fair Value Measurements Recurring | Level 2 | Municipal Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total debt securities	23,998	24,480
Fair Value Measurements Recurring | Level 2 | Yankee Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total debt securities	8,088	12,153
Fair Value Measurements Recurring | Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total equity securities, debt securities and cash equivalents	26,233	21,965
Fair Value Measurements Recurring | Level 3 | Preferred Stock Of Privately Held Company
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total debt securities	15,000
Fair Value Measurements Recurring | Level 3 | Redeemable Preferred Stock Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total debt securities	$ 11,233	$ 21,965

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	Sep. 30, 2022	Sep. 30, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value assets, transfers between levels, amount	$ 0	$ 0
Redeemable Preferred Stock Investment | Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Redeemable preferred stock investment unobservable	11,200,000
Preferred Stock Of Privately Held Company | Level 3 | Other Long-Term Assets
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investment in private securities unobservable input	$ 15,000,000

Fixed Assets - Major Classes of

Fixed Assets - Major Classes of Fixed Assets (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 117,773	$ 81,917
Less: Accumulated depreciation	(35,966)	(19,630)
Fixed assets, net	81,807	62,287
Medical Lab Equipment
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 48,570	35,930
Medical Lab Equipment | Minimum
Property Plant And Equipment [Line Items]
Useful life in years	1 year
Medical Lab Equipment | Maximum
Property Plant And Equipment [Line Items]
Useful life in years	12 years
Leasehold Improvements
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 11,175	4,003
Useful life in years	Shorter of lease term or estimated useful life
Computer Hardware
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 6,906	5,661
Computer Hardware | Minimum
Property Plant And Equipment [Line Items]
Useful life in years	1 year
Computer Hardware | Maximum
Property Plant And Equipment [Line Items]
Useful life in years	5 years
Computer Software
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 6,793	1,408
Computer Software | Minimum
Property Plant And Equipment [Line Items]
Useful life in years	1 year
Computer Software | Maximum
Property Plant And Equipment [Line Items]
Useful life in years	5 years
Building
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 6,731	6,731
Useful life in years	39 years
Aircraft
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 6,503	6,503
Useful life in years	7 years
Building Improvements
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 5,749	3,936
Building Improvements | Minimum
Property Plant And Equipment [Line Items]
Useful life in years	6 months
Building Improvements | Maximum
Property Plant And Equipment [Line Items]
Useful life in years	39 years
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 4,160	2,255
Furniture and Fixtures | Minimum
Property Plant And Equipment [Line Items]
Useful life in years	1 year
Furniture and Fixtures | Maximum
Property Plant And Equipment [Line Items]
Useful life in years	5 years
Automobile
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 811	825
Automobile | Minimum
Property Plant And Equipment [Line Items]
Useful life in years	2 years
Automobile | Maximum
Property Plant And Equipment [Line Items]
Useful life in years	7 years
Land Improvements
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 616	403
Land Improvements | Minimum
Property Plant And Equipment [Line Items]
Useful life in years	5 years
Land Improvements | Maximum
Property Plant And Equipment [Line Items]
Useful life in years	15 years
General Equipment
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 44	44
General Equipment | Minimum
Property Plant And Equipment [Line Items]
Useful life in years	3 years
General Equipment | Maximum
Property Plant And Equipment [Line Items]
Useful life in years	5 years
Land
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 7,500	7,500
Assets Not Yet Placed in Service
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 12,215	$ 6,718

Fixed Assets - Additional Infor

Fixed Assets - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense on fixed assets	$ 7.6	$ 2.5	$ 17.9	$ 6.7

Other Balance Sheet Accounts -

Other Balance Sheet Accounts - Schedule of Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Prepaid expenses	$ 8,399	$ 4,244
Reagents and supplies	7,509	12,206
Marketable securities interest receivable	2,733	2,743
Prepaid income taxes	2,055	1,716
Other receivable	699	1,403
Contract assets		237
Total	$ 21,395	$ 22,549

Other Balance Sheet Accounts _2

Other Balance Sheet Accounts - Schedule of Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Payable to a broker	$ 12,905
Other	716	$ 680
Total	$ 13,621	$ 680

Reporting Segment and Geograp_3

Reporting Segment and Geographical Information - Additional Information (Details)	9 Months Ended
	Sep. 30, 2022 Segment
Segment Reporting [Abstract]
Number of reporting segments	1

Reporting Segment and Geograp_4

Reporting Segment and Geographical Information - Summary of Revenue by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Revenue	$ 105,655	$ 227,868	$ 551,264	$ 740,913
United States
Segment Reporting Information [Line Items]
Revenue	101,515	223,685	540,801	731,084
Foreign
Segment Reporting Information [Line Items]
Revenue	$ 4,140	$ 4,183	$ 10,463	$ 9,829

Debt, Commitments and Conting_2

Debt, Commitments and Contingencies - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Debt, Commitments and Contingencies [Line Items]
Debt security investment outstanding borrowing amount			$ 15,000,000
Interest on loan withdrawn from margin account			1%
Payments for closing of escrow, financed under margin loan			$ 15,000,000
Interest rate			3%
Investment margin loan	$ 14,999,000		$ 14,999,000		$ 15,137,000
Interest expense	105,000	$ 30,000	185,000	$ 88,000
Notes payable, current portion	5,481,000		5,481,000		6,147,000
Non-cancelable purchase obligations	15,800,000		15,800,000
Reagents and Other Supplies
Debt, Commitments and Contingencies [Line Items]
Non-cancelable purchase obligations	5,200,000		5,200,000
Services
Debt, Commitments and Contingencies [Line Items]
Non-cancelable purchase obligations	3,200,000		3,200,000
Non-cancelable purchase obligations, payable within next twenty-four months	485,000		485,000
Software
Debt, Commitments and Contingencies [Line Items]
Non-cancelable purchase obligations	5,500,000		5,500,000
Medical Lab Equipment
Debt, Commitments and Contingencies [Line Items]
Non-cancelable purchase obligations, payable within twelve months	1,400,000		1,400,000
Xilong Scientific
Debt, Commitments and Contingencies [Line Items]
Notes payable	5,000,000		5,000,000
Xilong Scientific | FF Gene Biotech
Debt, Commitments and Contingencies [Line Items]
Interest expense	$ 75,000	$ 74,000	$ 231,000	$ 74,000
Debt instrument, interest rate terms			The notes payable to Xilong Scientific are due on December 31, 2022, and the interest rate on the loan is 4.97%.
Debt instrument, interest rate	4.97%		4.97%
Installment Sale Contract
Debt, Commitments and Contingencies [Line Items]
Notes payable	$ 3,800,000		$ 3,800,000		$ 0
Notes payable, current portion	$ 461,000		$ 461,000
Debt instrument, interest rate terms			The notes payable related to the installment sale are due in February 2030, and the interest rate is 1.08%.
Debt instrument, interest rate	1.08%		1.08%
Installment Sale Contract | Other Long-Term Liabilities
Debt, Commitments and Contingencies [Line Items]
Notes payable, noncurrent portion	$ 3,400,000		$ 3,400,000

Leases - Additional Information

Leases - Additional Information (Details)	9 Months Ended
	Sep. 30, 2022
Lessee Lease Description [Line Items]
Operating leases term of expiration	2028-03
Minimum | Building
Lessee Lease Description [Line Items]
Remaining terms including renewal options	3 months
Maximum | Building
Lessee Lease Description [Line Items]
Remaining terms including renewal options	16 months

Leases - Schedule of Operating

Leases - Schedule of Operating and Finance Lease Right-of-Use Asset, Short-term Lease Liabilities, and Long-term Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Leases [Abstract]
Operating lease ROU asset, net	$ 16,363	$ 7,141
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other long-term assets	Other long-term assets
Operating lease liabilities, short term	$ 6,184	$ 1,842
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued liabilities	Accrued liabilities
Operating lease liabilities, long term	$ 10,282	$ 5,344
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other long-term liabilities	Other long-term liabilities
Finance lease ROU asset, net	$ 3,010	$ 1,735
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other long-term assets	Other long-term assets
Finance lease liabilities, short term	$ 927	$ 332
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued liabilities	Accrued liabilities
Finance lease liabilities, long term	$ 2,050	$ 1,398
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other long-term liabilities	Other long-term liabilities

Leases - Schedule of Operatin_2

Leases - Schedule of Operating and Financing Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Leases [Abstract]
Operating lease cost	$ 1,770	$ 429	$ 3,674	$ 730
Finance lease cost:
Amortization of ROU assets	225	3	490	3
Interest on lease liabilities	31		66
Short-term lease cost	112	53	1,042	245
Total lease cost	$ 2,138	$ 485	$ 5,272	$ 978

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Information Related to Operating Leases and Finance Leases (Details)	Sep. 30, 2022
Leases [Abstract]
Weighted average remaining lease term - operating leases	3 years 4 months 20 days
Weighted average discount rate - operating leases	3.82%
Weighted average remaining lease term -finance lease	3 years 3 months 29 days
Weighted average discount rate - finance lease	3.98%

Leases - Schedule of Maturity A

Leases - Schedule of Maturity Analysis of Operating and Finance Lease Liabilities using Undiscounted Cash Flows on an Annual Basis (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Operating Leases
2022 (remaining 3 months)	$ 1,717
2023	6,579
2024	4,063
2025	2,112
2026	1,521
2027	1,360
Thereafter	217
Total lease payments	17,569
Less imputed interest	(1,103)
Total	16,466
Finance Lease
2022 (remaining 3 months)	207
2023	1,033
2024	1,026
2025	544
2026	366
Total lease payments	3,176
Less imputed interest	(199)
Total	$ 2,977

Leases - Schedule of Lease Inco

Leases - Schedule of Lease Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Leases [Abstract]
Lease income	$ 48	$ 78	$ 229	$ 315
Variable lease income		1	12	6
Total lease income	$ 48	$ 79	$ 241	$ 321

Leases - Schedule of Future Fix

Leases - Schedule of Future Fixed Lease Payments from Tenants for All Noncancelable Operating Leases (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Leases [Abstract]
2022 (remaining 3 months)	$ 40
2023	93
2024	3
Total	$ 136

Equity-Based Compensation - Sum

Equity-Based Compensation - Summary of Equity-Based Compensation Expenses as Part of Cost of Revenue and Operating Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total Equity-based compensation expense	$ 8,972	$ 4,374	$ 22,618	$ 10,862
Cost of Revenue
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total Equity-based compensation expense	2,475	962	6,183	2,328
Research and Development
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total Equity-based compensation expense	2,687	1,757	7,110	4,461
Selling and Marketing
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total Equity-based compensation expense	1,243	693	3,148	1,739
General and Administrative
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total Equity-based compensation expense	$ 2,567	$ 962	$ 6,177	$ 2,334

Provision for Income Taxes - Ad

Provision for Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 414,000	$ 37,545,000	$ 51,488,000	$ 127,647,000
Effective income tax rate	24%	23%	24%	24%

Income per Share - Reconciliati

Income per Share - Reconciliation of Basic and Diluted Income Per Share Computations (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Net income attributable to Fulgent	$ 1,719	$ 122,522	$ 167,235	$ 403,025
Weighted-average common shares—outstanding, basic	30,174	29,673	30,256	29,221
Weighted-average common shares—outstanding, diluted	30,867	31,170	31,107	30,906
Net income per common share, basic	$ 0.06	$ 4.13	$ 5.53	$ 13.79
Net income per common share, diluted	$ 0.06	$ 3.93	$ 5.38	$ 13.04

Income per Share - Anti-dilutiv

Income per Share - Anti-dilutive Securities Excluded from Calculation of Diluted Income Per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted income per share	7	5	10	5
Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted income per share	1,238	241	697	129

Related Parties - Additional In

Related Parties - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Apr. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
ANP Technologies, Inc., | Ming Hsieh
Related Party Transaction [Line Items]
Ownership percentage		20%		20%
AHMC Healthcare Inc. | Genetic Sequencing Services
Related Party Transaction [Line Items]
Revenue from related parties		$ 299,000	$ 762,000	$ 1,300,000	$ 2,600,000
Trade accounts receivable, net from related parties		197,000		197,000		$ 556,000
Fulgent Pharma LLC
Related Party Transaction [Line Items]
Related party costs		0	0	0	0
Due to related parties		66,000		66,000		679,000,000
Fulgent Pharma LLC | Research Development Service
Related Party Transaction [Line Items]
Expenses to transport employees and supplies		0	74,000	0	279,000
PTJ Associates Inc
Related Party Transaction [Line Items]
Expenses to transport employees and supplies		0	65,000	235,000	142,000
Accounts payable to related parties		0		0		0
ANP Technologies Inc
Related Party Transaction [Line Items]
Due to related parties		69,000		69,000		$ 0
Purchase of COVID-19 antigen rapid tests kits from related party		$ 120,000	$ 0	$ 280,000	$ 0
Fulgent Pharma Holdings | Ming Hsieh, the Chief Executive Officer and Chairman
Related Party Transaction [Line Items]
Percentage of ownership	100%

Goodwill and Acquisition-Rela_3

Goodwill and Acquisition-Related Intangibles - Summaries of Goodwill and Acquisitions-Related Intangibles Balances (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Goodwill And Intangible Assets [Line Items]
Goodwill	$ 120,313	$ 50,897
Acquisitions-related intangibles, net	87,853	35,914
Total intangible assets, net	87,853	35,914
Royalty-Free Technology
Goodwill And Intangible Assets [Line Items]
Acquisitions-related intangibles, gross	5,201	5,803
Less: accumulated amortization	(737)	(387)
Acquisitions-related intangibles, net	$ 4,464	5,416
Weighted-Average Amortization Period	10 years
Customer Relationships
Goodwill And Intangible Assets [Line Items]
Acquisitions-related intangibles, gross	$ 82,715	28,845
Less: accumulated amortization	(4,608)	(1,125)
Acquisitions-related intangibles, net	$ 78,107	27,720
Weighted-Average Amortization Period	13 years
Trade Name
Goodwill And Intangible Assets [Line Items]
Acquisitions-related intangibles, gross	$ 3,790	1,090
Less: accumulated amortization	(288)	(45)
Acquisitions-related intangibles, net	$ 3,502	1,045
Weighted-Average Amortization Period	8 years
In-Place Lease Intangible Assets
Goodwill And Intangible Assets [Line Items]
Acquisitions-related intangibles, gross	$ 360
Less: accumulated amortization	(29)
Acquisitions-related intangibles, net	$ 331
Weighted-Average Amortization Period	5 years
Laboratory Information System Platform
Goodwill And Intangible Assets [Line Items]
Acquisitions-related intangibles, gross	$ 1,860	1,860
Less: accumulated amortization	(434)	(155)
Acquisitions-related intangibles, net	$ 1,426	1,705
Weighted-Average Amortization Period	5 years
Purchased Patent
Goodwill And Intangible Assets [Line Items]
Acquisitions-related intangibles, gross	$ 28	31
Less: accumulated amortization	(5)	(3)
Acquisitions-related intangibles, net	$ 23	$ 28
Weighted-Average Amortization Period	10 years

Goodwill and Acquisition-Rela_4

Goodwill and Acquisition-Related Intangibles - Summary of Carrying Amount of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill, Beginning Balance	$ 50,897
Goodwill, Beginning Balance	50,897
Goodwill acquired during year	71,844
Net exchange differences	(2,428)
Goodwill, Ending Balance	120,313
Goodwill, Ending Balance	$ 120,313

Goodwill and Acquisition-Rela_5

Goodwill and Acquisition-Related Intangibles - Summary of Annual Amortization Expense For Acquisition-Related Intangibles (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Finite Lived Intangible Assets [Line Items]
2022 (remaining 3 months)	$ 1,960
2023	7,841
2024	7,841
2025	7,841
2026	7,536
2027	7,209
Thereafter	47,625
Acquisitions-related intangibles, net	$ 87,853	$ 35,914

Business Combinations - Additio

Business Combinations - Additional Information (Details) - USD ($) $ in Thousands			3 Months Ended		9 Months Ended
	Apr. 26, 2022	Apr. 16, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Business Acquisition [Line Items]
Goodwill			$ 120,313		$ 120,313		$ 50,897
Revenue			105,655	$ 227,868	551,264	$ 740,913
Operating income (loss)			352	159,273	$ 215,079	525,093
Customer Relationships
Business Acquisition [Line Items]
Estimated amortization life of identified intangible assets assumed					13 years
Trade Name
Business Acquisition [Line Items]
Estimated amortization life of identified intangible assets assumed					8 years
In-Place Lease Intangible Assets
Business Acquisition [Line Items]
Estimated amortization life of identified intangible assets assumed					5 years
Inform Diagnostics
Business Acquisition [Line Items]
Percentage of acquisition of outstanding equity	100%
Total purchase price payable		$ 170,000
Goodwill	$ 71,845
Identified intangible assets	57,060
Revenue	53,900
Operating income (loss)	11,200
Acquisition related transaction costs			166,000		$ 9,600
Other adjustments related to net income			0	579,000	772,000	1,700
Other adjustments related to revenue			0	$ 1,300	962,000,000	$ 3,000
Inform Diagnostics | Selling, General and Administrative Expenses
Business Acquisition [Line Items]
Acquisition related transaction costs			$ 166,000		$ 6,600
Inform Diagnostics | Customer Relationships
Business Acquisition [Line Items]
Identified intangible assets	$ 54,000
Estimated amortization life of identified intangible assets assumed	14 years
Inform Diagnostics | Trade Name
Business Acquisition [Line Items]
Identified intangible assets	$ 2,700
Estimated amortization life of identified intangible assets assumed	7 years
Inform Diagnostics | In-Place Lease Intangible Assets
Business Acquisition [Line Items]
Identified intangible assets	$ 360,000
Estimated amortization life of identified intangible assets assumed	5 years

Business Combinations - Summary

Business Combinations - Summary of Consideration Paid and Amount of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands		9 Months Ended
	Apr. 26, 2022	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Business Acquisition [Line Items]
Cash, net of cash received		$ 137,755	$ 61,868
Goodwill		$ 120,313		$ 50,897
Inform Diagnostics
Business Acquisition [Line Items]
Cash, net of cash received	$ 137,755
Net working capital	(15,024)
Fixed assets	20,242
ROU assets - operating	12,653
ROU assets - finance	1,183
Deferred tax assets	3,410
Other long-term assets	4,711
Identified intangible assets	57,060
Operating lease liabilities	(12,653)
Finance lease liabilities	(1,183)
Income tax payable	(40)
Other long-term liabilities	(4,449)
Recognized amounts of identifiable assets acquired and liabilities assumed, net	65,910
Goodwill	71,845
Total	$ 137,755

Business Combinations - Summa_2

Business Combinations - Summary of Unaudited Pro Forma Financial Information (Details) - Inform Diagnostics - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Business Acquisition [Line Items]
Revenue	$ 105,655	$ 261,809	$ 591,682	$ 851,660
Net income attributable to Fulgent	$ 1,885	$ 121,053	$ 164,120	$ 403,631
Basic earnings per common share attributable to Fulgent	$ 0.06	$ 4.08	$ 5.42	$ 13.81
Diluted earnings per common share attributable to Fulgent	$ 0.06	$ 3.88	$ 5.28	$ 13.06

Stock Repurchase Program - Addi

Stock Repurchase Program - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2022	Mar. 31, 2022
Stockholders' Equity Note [Abstract]
Stock repurchase program, authorized amount				$ 250,000,000
Number of shares repurchased	780,000		995,000
Aggregate cost of shares repurchased	$ 34,702,000	$ 10,577,000	$ 45,300,000
Stock repurchase program, remaining authorized amount	$ 204,700,000		$ 204,700,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended		9 Months Ended
	Nov. 07, 2022	Oct. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2022
Subsequent Event [Line Items]
Number of shares repurchased			780,000		995,000
Aggregate cost of shares repurchased			$ 34,702	$ 10,577	$ 45,300
Subsequent Event
Subsequent Event [Line Items]
Number of shares repurchased		244,000
Aggregate cost of shares repurchased		$ 9,100
Fulgent Pharma Holdings | Subsequent Event
Subsequent Event [Line Items]
Business combination, consideration transferred	$ 100,000
Cash consideration	43,400
Stock consideration	30,700
Fulgent Pharma Holdings | Subsequent Event | Restricted Stock Units
Subsequent Event [Line Items]
RSU assumed, value	$ 25,900
Restricted stock units vesting period	4 years
Fulgent Pharma Holdings | Subsequent Event | Paul Kim | Restricted Stock Units
Subsequent Event [Line Items]
RSU assumed	77,585
Fulgent Pharma Holdings | Subsequent Event | Jian Xie | Restricted Stock Units
Subsequent Event [Line Items]
RSU assumed	129,309
Fulgent Pharma Holdings | Subsequent Event | Hanlin Gao | Restricted Stock Units
Subsequent Event [Line Items]
RSU assumed	51,723
Fulgent Pharma Holdings | Subsequent Event | Other employees | Restricted Stock Units
Subsequent Event [Line Items]
RSU assumed	117,398
Fulgent Pharma Holdings | Subsequent Event | Consultants | Restricted Stock Units
Subsequent Event [Line Items]
RSU assumed	286,998